Last updated: Apr 20, 2020 - 02:00 BST

Title Indication Intervention Actions PatientSelection Sponsor Collaborator Country StartDate EndDate Identifiers Phase Recruitment Status Sites Trial Duration Enrollment Count Contacts LastChanged
Lung ultrasound versus CT scan in COVID-19 disease Coronavirus disease 19 infection, Viral pneumonia Lung UltraSound alone, low-dose CT-scan alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboudumc Netherlands 2020-03-15 2020-06-30 2020-6372, NL8497 Phase Not Applicable Recruiting 1 3 Months 200 Frank Bosch 2020-04-17
BCG Vaccine for Health Care Workers as Defense Against SARS-COV2 Coronavirus disease 19 infection BCG vaccine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Baylor College of Medicine Harvard University, MD Anderson Cancer Center, University Medical Centre St Radboud US 2020-04-30 2021-11-30 H-47454, NCT04348370 Phase 4 Clinical Not yet recruiting 0 19 Months 700 Andrew DiNardo, MD, Anna Mandalakas, MD, Ashish Kamat, MD, Marisa Lozano, Megan Murray, MD, MPH, Seth Lerner, MD 2020-04-17
CounterCovid19: Countering Lung Damage in COVID-19 infection (CounterCovid) studyCountering Lung Damage in COVID-19 infection study Coronavirus disease 19 infection, Lung injury imatinib alone Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Amsterdam UMC Netherlands 2020-03-31 2020-06-30 2020.158, CounterCovid19, NL8491 Phase 3 Clinical Recruiting 1 3 Months 386 Harm Jan Bogaard 2020-04-17
PVC-RAM: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial Coronavirus disease 19 infection Virtual Care and Remote Automated Monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Population Health Research Institute Hamilton Health Sciences Corp, McMaster University Canada 2020-04-30 2020-09-30 NCT04344665, PVC-RAM, V1.0, 2020.04.06 Phase Not Applicable Not yet recruiting 2 5 Months 900 Michael McGillion, PhD, PJ Devereaux, PhD, Valerie Harvey, BSc 2020-04-17
LUS-CC: Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients Coronavirus disease 19 infection, Viral pneumonia Lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboudumc Netherlands 2020-03-15 2020-05-31 2020-6371, LUS-CC, NL8498 Phase Not Applicable Recruiting 1 2 Months 20 Frank Bosch 2020-04-17
A clinicla trial of repurposed NP-120 for teh treatment of acute lung injury due to COVID-19 Acute lung injury, Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals Phase Not Applicable Planned 0 2020-04-17
Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak Coronavirus disease 19 infection Ayurveda Self-Management alone, Yoga breathing alone, paracetamol alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Aarogyam UK UK 2020-02-26 2020-03-30 AU08, NCT04345549 Phase Not Applicable Completed 1 1 Month 18 Jaydeep Joshi, Neha Sharma 2020-04-17
CATNAP: COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning Coronavirus disease 19 infection Self-prone position recommendation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Boston University US 2020-04-30 2020-07-31 CATNAP, H-40070, NCT04344587 Phase Not Applicable Not yet recruiting 0 3 Months 380 Allan J Walkey, MD, Michael Garcia, MD, Nicholas A Bosch, MD 2020-04-17
LEEP-COVID: Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 Coronavirus disease 19 infection, Respiratory failure Multifrequency Bioimpedance Spectroscopy alone, Q-NRG metabolic cart device alone, muscle sound ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University US 2020-04-17 2020-12-01 LEEP-COVID, NCT04350073, PRO00105221 Phase Not Applicable Not yet recruiting 0 7 Months 120 Jeroen Molinger, Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM, Paul Wischmeyer, MD, EDIC, FASPEN, FCCM 2020-04-17
ReportAge-COVID: Clinical and Biological Predictors of COVID-19 Disease in Older Patients Coronavirus disease 19 infection Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istituto Nazionale di Ricovero e Cura per Anziani Italy 2020-04-30 2020-12-31 INRCA_01_2020, NCT04348396, ReportAge-COVID Phase Not Applicable Not yet recruiting 1 8 Months 300 Antonio Cherubini, MD, Silvia Bustacchini, MD 2020-04-18
UPSAT: Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation Coronavirus disease 19 infection, Hypoxia, Respiratory failure postural positioning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johns Hopkins University US 2020-04-20 2021-05-31 IRB00246834, NCT04344561, UPSAT Phase Not Applicable Not yet recruiting 0 13 Months 70 Luu Pham, MD, Trishul Siddharthan, MD 2020-04-17
COVIDIMMUNE: Evaluating the Immune Response for COVID-19 Coronavirus disease 19 infection 2019-NCoV IgM/IgG (MAGLUMI) alone, Anti-SARS-CoV-2 (EuroImmun) alone, COVID-19 IgM/IgG (DIA PRO) alone, Coronavirus COVID-19 IgG ELISA (IBL) alone, Immunocomb (BioGal) alone, NADAL COVID-19 IgG/Igm (Nal Von Minden) alone, Rt-PCR kit alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assaf-Harofeh Medical Center Israel 2020-04-20 2020-12-31 105-20-ASF, COVIDIMMUNE, NCT04348422 Phase Not Applicable Not yet recruiting 1 8 Months 1000 Amir Hadanny, MD, Prof. Shay Efrati, Shai Efrati, MD 2020-04-17
Saved From COVID-19 Coronavirus disease 19 infection chloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Columbia University US 2020-04-30 2021-04-30 AAAS9992, NCT04349371 Phase 2 Clinical Recruiting 0 12 Months 350 Anca Askanase, MD, MPH, Anca D. Askanase, MD, MPH, Tommy Chen 2020-04-17
PRODEX: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Coronavirus disease 19 infection, Respiratory failure dexmedetomidine alone Alpha 2 adrenoceptor agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Limoges France 2020-04-20 2020-11-20 87RI20_0011 (PRODEX), NCT04350086, PRODEX Phase 4 Clinical Not yet recruiting 1 7 Months 10 Paul-Antoine QUESNEL, MD 2020-04-17
Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19 Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Hope Biosciences Stem Cell Research Foundation US 2020-04-23 2021-04-30 ALLOGENEIC COVID-19 PROTECTION, NCT04348435 Phase 2 Clinical Recruiting 0 12 Months 100 Thanh Cheng, MD 2020-04-17
Telerehabilitation for Patients Diagnosed With Coronavirus Coronavirus disease 19 infection Telerehabilitation alone, exercise brochure alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Istinye Universitesi 2020-04-10 2020-07-31 009, NCT04346927 Phase Not Applicable Not yet recruiting 0 3 Months 30 Yasemin Çırak 2020-04-17
Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Shanghai East Hospital China 2020-03-01 2020-04-30 ChiCTR2000031707 Phase Not Applicable Recruiting 1 2 Months 47 Chen Li 2020-04-17
Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine Coronavirus disease 19 infection, Viral pneumonia Traditional Chinese medicine sachet alone, general basic epidemic prevention measures alone, oral and nasal spray alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Beijing institute of Traditional Chinese Medicine China 2020-04-01 2020-12-31 ChiCTR2000031955 Phase 0 Clinical Recruiting 1 9 Months 3808 Lingru Li 2020-04-17
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Prevent Senior Private Operadora de Saúde LTDA Brazil 2020-04-20 2020-07-31 HIAPRE0420OR, NCT04348474 Phase 0 Clinical Not yet recruiting 1 3 Months 200 Luciana Ferrara, Rafael Souza, MD, PhD, Álvaro Razuk Filho, MD, PhD 2020-04-17
Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people Coronavirus disease 19 infection, Viral pneumonia Ke-Gan-Li-Yan oral liquid alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fifth Affiliated Hospital, Sun Yat-Sen University China 2020-04-01 2020-08-31 ChiCTR2000031982, ChiMCTR2000003216 Phase 4 Clinical Not yet recruiting 1 5 Months 240 Hu Guanying, Huang Mingxing 2020-04-17
Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs Coronavirus disease 19 infection, Viral pneumonia Asian Ancestry Fujian Provincial Hospital China 2020-02-05 2020-02-10 ChiCTR2000031896 Phase Not Applicable No longer recruiting 1 923 Miao Xing 2020-04-17
Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community Coronavirus disease 19 infection Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese University of Hong Kong Health and Medical Research Fund, Hong Kong China 2020-04-15 2021-04-14 ChiCTR2000031928 Phase Not Applicable Not yet recruiting 1 12 Months 3000 Peter Choi Ching Lam, Prof. KS Chan Paul 2020-04-17
POINT-C: ICU Trial in Critical Ill COVID-19 Patients Cardiovascular disease, Coronavirus disease 19 infection blood sampling alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Graz Austria 2020-04-08 2020-07-31 250320, NCT04349982, POINT-C Phase Not Applicable Recruiting 1 3 Months 50 Christoph Klivinyi, Dr., Martin Rief, Dr, Martin Rief, Dr. 2020-04-17
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc US 2020-04-16 2020-12-31 NCT04349631, PROTECTION AGAINST COVID-19 Phase 2 Clinical Recruiting 0 8 Months 56 Thanh Cheng, MD 2020-04-18
Resi-CoV: Resilience During Covid-19 Epidemic Coronavirus disease 19 infection CD-RISC 25 questionnaire alone Healthy volunteers accepted University Hospital, Angers 2020-04-15 2020-05-25 2020-A00831-39, NCT04349163, Resi-CoV Phase Not Applicable Not yet recruiting 0 1 Month 280 Delphine Douillet, MD 2020-04-17
A COVID-19 Symptom, Exposure and Immune Response Registry Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) ObvioHealth 2020-04-20 2021-05-01 NCT04348942, OBVIO-OBV-001 Phase Not Applicable Not yet recruiting 0 12 Months 10000 Joshua Lowndes, MA, MS, Kamalia Sazali, MS 2020-04-17
Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National Institute of Dental and Craniofacial Research National Institutes of Health Clinical Center US 2020-04-21 2020-07-01 20-D-0094, 200094, NCT04348240 Phase Not Applicable Recruiting 0 2 Months 30 Blake M Warner, D.D.S. 2020-04-17
APPROVE-CARE: Awake Prone Positioning to Reduce Invasive Ventilation in COVID-19 Induced Acute Respiratory failure Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure Prone positioning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University College Galway Ireland 2020-04-11 2021-05-11 APPROVE-CARE, APPROVE-CARE-2020, NCT04347941 Phase Not Applicable Not yet recruiting 1 13 Months 200 Bairbre A McNicholas, MB BCh PhD, David Cosgrave, MB BCh FARSI 2020-04-17
Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 Coronavirus disease 19 infection nitazoxanide alone, standard care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azidus Brasil Centro De Genomas, Emilio Ribas Infectious Diseases Institute, Farmoquimica SA, Hospital Vera Cruz Brazil 2020-04-12 2020-06-30 NCT04348409, NITFQM0320OR Phase 2 Clinical Not yet recruiting 2 2 Months 50 Florentino de Araujo Cardoso Filho, MD, PhD, Luciana Ferrara, Ricardo Diaz, MD, PhD, Sérgio Cimerman, MD, PhD 2020-04-17
CoPE It: An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection CoPE It training alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Klinik für Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universität Duisburg-Essen Germany 2020-04-23 20-9243-BO, CoPE It, DRKS00021301 Phase Not Applicable Not yet recruiting 2 90 Alexander Bäuerle, Martin Teufel 2020-04-17
Analysis of clinical characteristics and therapeutic effect of nine cases of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Affiliated Hospital of Zunyi Medical College National Natural Science Foundation of China China 2019-12-31 2020-03-01 ChiCTR2000031930 Phase Not Applicable No longer recruiting 1 2 Months 9 Chen Hongjun, Chen Miao 2020-04-17
An Open, Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19 Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome Variable regimens including Dalargin , azithromycin , hydroxychloroquine , tocilizumab Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Burnasyan Federal Medical Biophysical Center Russian Federation 2020-04-08 2020-12-31 DAL-05-04-2020, NCT04346693 Phase 3 Clinical Recruiting 1 8 Months 320 Tatyana Astrelina 2020-04-18
Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection Coronavirus disease 19 infection triiodothyronine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa Attikon Hospital Greece 2020-05-02 2021-05-31 NCT04348513, T3INJ-02/THYSUPPORT, Thy-Support Phase 2 Clinical Not yet recruiting 1 12 Months 60 Apostolos Armaganidis, MD, Georgia Kostopanagiotou, MD 2020-04-18
Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Saint Etienne France 2020-03-30 2020-001281-11, 20CH065 Phase 4 Clinical Recruiting 1 50 project manager 2020-04-17
A potential clinical trial of SARS-CoV-2 3C-like (3CL) protease inhibitors for the potential iv treatment of COVID-19 caused by SARS-CoV-2 (2019-nCoV) Coronavirus disease 19 infection SARS-CoV-2 3C-like (3CL) protease inhibitors (Coronavirus disease 19 infection), Pfizer alone Protease inhibitor Pfizer Inc 2020-09-30 Phase Not Applicable Planned 0 2020-04-17
CORIPLASM: Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris Etablissement Francais du Sang France 2020-04-14 2020-06-01 2020-001246-18, APHP200375-10, CORIPLASM, NCT04345991 Phase 2 Clinical Not yet recruiting 1 1 Month 120 Karine LACOMBE 2020-04-17
Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): A Randomized Controlled Trial Coronavirus disease 19 infection, Viral pneumonia Chinese herbal tea alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) China Academy of Chinese Medical Sciences China 2020-04-16 2020-12-31 ChiCTR2000031944, ChiMCTR2000003212 Phase Not Applicable Recruiting 1 8 Months 2000 Liu Bin, Lu Cheng 2020-04-17
A clinical study of haNK cells combined with convalescent plasma for the treatment in mild, moderate to the severe or critically ill COVID-19 patients Coronavirus disease 19 infection convalescent plasma plus haNK cells (cancer), NantKwest/Fox Chase Cancer Center NantKwest Inc US 2020-06-30 Phase Not Applicable Planned 0 2020-04-17
Efficacy and safety of convalescent plasma in the treatment of COVID-19 Coronavirus disease 19 infection, Viral pneumonia convalescent plasma alone, conventional therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Artesh University of Medical Sciences Iran 2020-04-13 IR.AJAUMS.REC.1399.007, IRCT20200404046948N1 Phase 3 Clinical Recruiting 3 60 Ebrahim Hazrati, Mohammad Aminianfar, Neginsadat Hosseini Mohammadi, Ramin Hamidi Farahani, Saeed Soleimani Meigouni, Seyed Javad Hosseini Shokouh 2020-04-17
PSI RECORd-XP: Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional, Descriptive Study Coronavirus disease 19 infection Healthy volunteers accepted CHU De Nantes France 2020-04-15 2020-06-15 NCT04348552, PSI RECORd-XP, RC20_0183 Phase Not Applicable Not yet recruiting 1 2 Months 1000 Jean-Pascal FOURNIER, Doctor 2020-04-17
Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Female International Peace Maternity and Child Health Hospital, Renmin Hospital of Wuhan University, The Central Hospital of Wuhan, Tongji Medical College, Wuhan Children’s Hospital China 2020-04-15 2020-04-30 ChiCTR2000031954 Phase Not Applicable Recruiting 3 30 He-Feng Huang, Yan-Ting Wu 2020-04-17
BLAST COVID-19: Beaumont Health Large-scale Automated Serologic Testing for COVID-19 Coronavirus disease 19 infection EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits alone, EUROIMMUN assay alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) William Beaumont Hospitals US 2020-04-30 2021-06-30 2020-134, BLAST COVID-19, NCT04349202 Phase Not Applicable Recruiting 0 14 Months 50000 Matthew Sims, MD, PhD, Maureen Cooney, RN, BSN 2020-04-18
COVID-2Pro: Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID-19 for Health Professionals Coronavirus disease 19 infection hydroxychloroquine (HCQ) alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Abderrahmane Mami Hospital Tunisia 2020-04-15 2020-07-15 ABDERRAHMANEMH, COVID-2Pro, NCT04349228 Phase 3 Clinical Not yet recruiting 2 3 Months 530 Dr Jalila Ben Khelil, Eshmoun Clinical Research Centre, Souad Dziri, Dr 2020-04-18
A clinical study of N-803 in COVID-19 patients with mild, moderate to the severe or critically ill state Coronavirus disease 19 infection ALT-803 alone IL-15 receptor agonist, IL-15 receptor modulator NantKwest Inc 2020-06-30 Phase Not Applicable Planned 0 2020-04-17
ARCHAIC: An open-label, randomized, controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection chloroquine alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Medisch Centrum Utrecht The Netherlands Organisation for Health Research and Development Netherlands 2020-04-12 2021-04-12 ARCHAIC, NL73529.041.20, NL8490 Phase 3 Clinical Not yet recruiting 1 12 Months 950 Jesper Weehuizen 2020-04-17
Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus) Coronavirus disease 19 infection selinexor alone Exportin 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Karyopharm Therapeutics Inc 2020-04-30 2020-08-31 2020-001411-25, NCT04349098, XPORT-COV-1001 Phase 2 Clinical Not yet recruiting 0 4 Months 230 Dayana Michel, Jatin Shah, Chief Medical Officer, Sharon Shacham, President and CSO 2020-04-19
Using eHealth to support COVID-19 self-assessment and collection of self-reported health data Coronavirus disease 19 infection Interactive Studios Netherlands 2020-03-23 2020-06-30 20.039, NL8501, TBA Phase Not Applicable Recruiting 1 3 Months 2000 Thomas Timmers 2020-04-17
Covid-19 en ACE remmers: The use of ACE2 receptor increasing medication at hospital admission and mortality rates in COVID-19 patiënts Coronavirus disease 19 infection Noordwest Ziekenhuisgroep Netherlands 2020-03-18 2020-09-18 2020.165, Covid-19 en ACE remmers, NL8512 Phase Not Applicable Recruiting 1 6 Months 400 Diederik van Wijk 2020-04-17
Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia canakinumab alone Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azienda Unita Sanitaria Locale Della Romagna 2020-04-30 2020-09-30 CANASCOV, NCT04348448 Phase Not Applicable Not yet recruiting 0 5 Months 100 2020-04-17
PreToVid: Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective, randomized trial Coronavirus disease 19 infection, Hypoxia, SARS coronavirus infection tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Roche Holding AG, University Medical Center Groningen Netherlands 2020-04-06 2020-12-31 NL8504, PreToVid Phase 3 Clinical Recruiting 1 8 Months 354 Margriet Dijkstra 2020-04-17
FMTVDM: The Fleming (FMTVDM) Directed CoVid-19 Treatment Protocol Coronavirus disease 19 infection, Viral pneumonia convalescent plasma alone, interferon alfa-2b alone, losartan alone, methylprednisolone alone, remdesivir alone, tocilizumab alone, Variable regimens including azithromycin , clindamycin , doxycycline , hydroxychloroquine , primaquine Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, Interferon alpha ligand modulator, RNA polymerase modulator The Camelot Foundation US 2020-04-11 2020-11-11 FMTVDM, FMTVDM2020, NCT04349410 Phase 2/Phase 3 Clinical Recruiting 0 7 Months 500 RM Fleming, MD, Principle Investigator, Richard M Fleming, PhD, MD, JD 2020-04-17
COVID-19 in rheumatic patients: a prospective, cohort study Ankylosing spondylitis, Coronavirus disease 19 infection, Psoriatic arthritis, Rheumatoid arthritis, SARS coronavirus infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jan van Breemen Institute Netherlands 2020-04-13 2021-04-13 2020.169 - NL73521.029.20, NL8513, TBA Phase Not Applicable Not yet recruiting 3 12 Months 8000 Femke Hooijberg 2020-04-17
How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU? Coronavirus disease 19 infection enhanced hygiene measures alone Hôpital Universitaire Fattouma Bourguiba Tunisia 2020-03-01 2020-07-04 MALEK KHEMILI, NCT04348227 Phase Not Applicable Recruiting 1 4 Months 120 Malek Khemili, Resident 2020-04-17
Evaluation the effect of asafoetida in the treatment of coronavirus infection Coronavirus disease 19 infection Variable regimens including asafoetida (Mashhad School of Pharmacy) , azithromycin , hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.071, IRCT20200413047053N1 Phase 2 Clinical Not yet recruiting 1 60 Dr. Dehghan Nayeri, Mehrdad Iranshahi, Mohsen Tafaghodi 2020-04-17
CWC-19: COPING With COVID-19 Coronavirus disease 19 infection crisis management coaching alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University US 2020-04-13 2020-06-30 CWC-19, NCT04343690, PRO00105319 Phase Not Applicable Not yet recruiting 0 2 Months 100 Erika Ratcliffe, Patty Lee, MD, Sangeeta Joshi, MD 2020-04-17
Tocilizumab-Corticosteroids COVID-19 Trial Coronavirus disease 19 infection tocilizumab alone National Institutes of Health Malaysia 2020-04-27 2020-10-30 54656, NMRR-20-735-54656 Phase 3 Clinical Not yet recruiting 1 6 Months 310 Dr Suresh Kumar, Norazida binti Ab. Rahman 2020-04-17
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19 Coronavirus disease 19 infection, Respiratory disease routine treatment alone, umifenovir alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Center for Progress and Development of Iran Iran 2020-03-30 IR.BMSU.REC.1399.037, IRCT20080901001165N46 Phase 3 Clinical Recruiting 1 200 Morteza Pirali, Parisa Kianpour, Yunes Panahi 2020-04-17
Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King Fahad Specialist Hospital Dammam Johns Hopkins Aramco Healthcare, King Fahad Medical City, King Fahad National Guard Hospital, King Fahd Military Medical Complex, King Faisal Specialized Hospital & Research Center, King Faisal University, King Khalid University Hospital, King Saud University, Taibah University Saudi Arabia 2020-04-12 2021-04-11 HAEM0321, NCT04347681 Phase 2 Clinical Not yet recruiting 10 12 Months 40 Ahmed Alsagheir, MD, Arwa Nabhan, MD, Hani Al-Hashmi, MD, Hazza AlZahrani, MD, Jawaher AlOtaibi, MD, Mahammad Awadallah, MSc, Mohammed Albalawi, MD, Mona Alfaraj, MD, Nawal AlShehry, MD, Nour AlMozain, MD, Rehab Al-Ansari, MD, Yem Abulhamayel, MD 2020-04-17
ATTAC-Co: Pro-thrombotic Status in Patients With SARS-Cov-2 Infection Coronavirus disease 19 infection, Respiratory failure, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Azienda Ospedaliero-Universitaria di Ferrara Italy 2020-04-08 2021-06-30 250320, ATTAC-Co, NCT04343053 Phase Not Applicable Recruiting 1 14 Months 60 Gianluca Campo, MD, Marco Contoli, MD, Savino Spadaro, MD, Veronica Lodolini 2020-04-17
Early Extubation for Patients With Acute Hypoxemic Respiratory Failure Coronavirus disease 19 infection, Hypoxia, Respiratory failure air flow meter alone, arterial blood gas sampling alone, endotracheal intubation alone, helmet alone, non-invasive ventilation alone, oxygen therapy alone, positive-end expiratory pressure valve alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-15 2021-06-01 20-0594, NCT04349332 Phase Not Applicable Not yet recruiting 0 13 Months 108 Anne Pohlman, MSN, Bhakti Patel, MD 2020-04-17
Battle Against COVID-19 Using Mesenchymal Stromal Cells Coronavirus disease 19 infection, Respiratory distress syndrome allogeneic and expanded adipose tissue-derived mesenchymal stromal cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz Clinica Universidad de Navarra, Fundacion De La Comunitat Valenciana Para La Gestión De Instituto De Investigación Sanitaria Y Biomédica De Alicante (Fundación Para La Gestión De Isabial), Hospital General Universitario De Alicante, Hospital General Universitario Gregorio Marañon, Hospital Universitario Virgen de la Arrixa, University Hospital of Salamanca 2020-04-06 2020-09-30 BALMYS-19, NCT04348461 Phase 2 Clinical Not yet recruiting 0 5 Months 100 Barbara Juan, MD, Mireia Arcas 2020-04-17
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 Coronavirus disease 19 infection, Rhinopharyngitis Johnson's baby shampoo nasal irrigation therapy alone, saline nasal irrigation therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Vanderbilt University Medical Center, US US 2020-05-31 2022-06-30 NCT04347538, PENDING IRB Phase Not Applicable Not yet recruiting 0 25 Months 90 Justin H. Turner, MD, PhD, Kate Von Wahlde, MJ, CCRP, Kyle Kimura, MD 2020-04-17
LACCTT: Lagos COVID-19 Chloroquine Treatment Trial Coronavirus disease 19 infection Chloroquine phosphate alone, Hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Lagos State University Nigerian Institute of Medical Research Nigeria 2020-04-17 2020-10-16 LACCTT, PACTR202004801273802 Phase 3 Clinical Not yet recruiting 1 6 Months 600 Akin Abayomi, Hussein AbdurRazzaq, Samuel Anya 2020-04-17
Q-PROTECT: Qatar Prospective, RCT Of Therapy Eliminating Covid Transmission Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hamad Medical Corp Qatar 2020-04-14 2020-05-30 MRC-05-001, NCT04349592, Q-PROTECT Phase 2 Clinical Not yet recruiting 1 1 Month 456 Tim Richard Edmund Harris 2020-04-17
Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-01 FMASU P18A/ 2020, NCT04348214 Phase Not Applicable Not yet recruiting 1 7 Months 3000 Fatma Soliman Elsayed Ebeid 2020-04-17
COVID-19 Antibody Self-testing Using Virtual Point-of-care Coronavirus disease 19 infection COVID-19 IgM/IgG rapid testing alone, telemedicine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Neuroganics LLC US 2020-04-30 2021-04-30 2020/03/18, NCT04348864 Phase Not Applicable Recruiting 0 12 Months 100 Donald Cooper, Ph.D., Joe Ramos, MD/JD 2020-04-17
save: Prevention of severe respiratory failure in Covid-19 Coronavirus disease 19 infection, Respiratory failure Bactrimel plus anakinra Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hellenic Institute for the Study of Sepsis Greece 2020-04-15 2020-001466-11, SAVE, save Phase 2 Clinical Recruiting 1 100 President of the Board 2020-04-17
FAV-001: Efficacy and Safety of Favipiravir in Management of COVID-19 Coronavirus disease 19 infection favipiravir alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-01 FAV-001, FMASU P14 / 2020, NCT04349241 Phase 3 Clinical Not yet recruiting 1 7 Months 100 Hany Dabbous 2020-04-17
Effect of Methylprednisolone on Treatment of COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome methylprednisolone‎ alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-03-28 IR.TUMS.VCR.REC.1399.054, IRCT20200404046947N1 Phase 3 Clinical Recruiting 3 40 Abdorahman Rostamian, Ahmadreza Jamshidi, Mahdi Mahmoudi, Maryam Akhtari, Maryam Edalatifard, Zohre Naderi, mohammad ali sahraian 2020-04-17
COVID STEROID: Hydrocortisone for COVID-19 and Severe Hypoxia Coronavirus disease 19 infection, Hypoxia hydrocortisone alone, standard care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Scandinavian Critical Care Trials Group Aarhus University Hospital, Copenhagen Trial Unit, Koebenhavns Universitet, Rigshospitalet, Denmark Denmark 2020-04-15 2021-12-30 2020-001395-15, COVID STEROID, NCT04348305, RH-ITA-008 Phase 3 Clinical Not yet recruiting 3 20 Months 1000 Anders Perner, MD, PhD, Maj-brit N Kjær, RN, MSc, Marie Warrer Petersen, MD, PhD, Professor 2020-04-17
Emocovid: Emotional Burden of Healthcare Professionals and Covid Infection 19 Anxiety disorder, Coronavirus disease 19 infection University Hospital, Limoges France 2020-04-15 2021-06-15 87RI20-0015/EMOCOVID, Emocovid, NCT04350099 Phase Not Applicable Not yet recruiting 2 14 Months 200 Anne Laure Fauchais, MD, Anne-Laure FAUCHAIS, MD, Philippe NUBUKPO, MD, Stéphanie DUMONTEIL 2020-04-17
Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease Coronavirus disease 19 infection clazakizumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cedars-Sinai Medical Center US 2020-04-21 2021-03-31 00000644, NCT04348500 Phase 2 Clinical Not yet recruiting 0 11 Months 60 Noriko Ammerman, PharmD, Stanley Jorda 2020-04-17
SR-NOCS: Observational, clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients Coronavirus disease 19 infection robotic autonomous naso-oropharyngeal swab collection alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Klinikum rechts der Isar der Technischen Universitaet Muenchen Technical University of Munich Germany 2020-04-01 152/20 S-KH, DRKS00021420, SR-NOCS Phase 1 Clinical Recruiting 1 30 Dirk Wilhelm 2020-04-17
COVID19-BMT: Role of Immune and Inflammatory Response in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 Coronavirus disease 19 infection blood sampling alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Great Ormond Street Hospital for Children NHS Foundation Trust UK 2020-04-15 2021-01-15 20BO08, COVID19-BMT, NCT04349540 Phase Not Applicable No longer recruiting 1 9 Months 40 2020-04-17
COVVA: Occupational health and safety among health care personnel in a COVID-19 pandemic Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidad de Valladolid Spain 2020-04-01 2020-04-22 COVVA, ISRCTN18348009, V_01_2020_REF.03.V_02 Phase Not Applicable No longer recruiting 2 80 Prof Martín-Rodríguez 2020-04-17
BREATHE: An adaptive,pivotal, randomized, placebo-controlled, double-blind, multicenter clinical study to assess the impact of intravenous gimsilumab on mortality in COVID-19 patients with lung injury or ARDS Acute lung injury, Adult respiratory distress syndrome, Coronavirus disease 19 infection gimsilumab alone GM-CSF ligand inhibitor Roivant Sciences Ltd US BREATHE Phase Not Applicable Recruiting 0 270 Dr. Gerard Criner 2020-04-17
A randomized, double-blind, placebo, parallel-controlled, phase I/II clinical trial to assess safety and efficacy of COVID-19 vaccine (inactivated, Vero cells) in Chinese healthy subjects for the treatment of COVID-19 infection Coronavirus disease 19 infection COVID-19 vaccine (inactivated, Vero cells/intramuscular), Wuhan Institute of Biological Products/Wuhan Institute of Virology, CAS alone Healthy volunteers accepted, Asian Ancestry Wuhan Institute of Biological Products Co Ltd China Phase 1/Phase 2 Clinical Recruiting 1 336 Xia Shengli 2020-04-17
Effect of a Brief Problem Management Intervention on COVID 19-Related Anxiety and Depression Anxiety disorder, Coronavirus disease 19 infection, Depression Problem Management Plus alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) UNSW Sydney National Health and Medical Research Council Australia 2020-04-20 ACTRN12620000468921p Phase Not Applicable Not yet recruiting 1 140 Prof Richard Bryant 2020-04-17
Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus Coronavirus disease 19 infection Nasodine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Firebrick Pharma Pty Ltd Australia 2020-04-20 ACTRN12620000470998p, FBP-004 Phase 0 Clinical Not yet recruiting 1 20 Prof Peter Friedland 2020-04-17
A clinical study of stem cells to treate hospitalized patients with COVID-19 infection Coronavirus disease 19 infection stem cells, Calidi Biotherapeutics Inc alone Personalized Stem Cells Inc Calidi Biotherapeutics Inc US 2020-05-31 Phase Not Applicable Planned 0 2020-04-16
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) Coronavirus disease 19 infection povidone-iodine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stanford University US 2020-05-31 2020-08-31 IRB-56134, NCT04347954 Phase 1/Phase 2 Clinical Not yet recruiting 0 3 Months 45 Neelaysh Vukkadala, MD, Peter H Hwang, MD 2020-04-17
UPMC-REMAP-COVID19: A novel clinical trial to evaluate the effect of hydroxychloroquine in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection hydroxycloroquine alone, immunomodulators alone, standard of care alone, steroids alone University of Pittsburgh School of Medicine US UPMC-REMAP-COVID19 Phase Not Applicable Not yet recruiting 0 Derek Angus 2020-04-16
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients Coronavirus disease 19 infection, Viral pneumonia anti-coronavirus antibody (immunoglobulin) therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ospedale Papa Giovanni XXIII Aferetica Srl Italy 2020-04-30 2020-07-31 DFPP COVID 19, NCT04346589 Phase Not Applicable Not yet recruiting 5 3 Months 10 Anna Falanga, MD, Annalisa Perna, Stat., Annapaola Callegaro, MD, Claudio Farina, MD, Diego Curto, MD, Diego Curtò, MD, Ferdinando Luca Lorini, MD, Giuseppe Remuzzi, MD, Lorenzo Grazioli, MD, Luca Barcella, MD, Marina Marchetti, Biol. Sci.D., Marina Noris, Ch., Miriam Galbusera, Biol.Sci. D., Piero Luigi Ruggenenti, Piero Luigi Ruggenenti, MD, Stefano Rota, MD 2020-04-18
Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression online mindfulness session alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chinese University of Hong Kong Hong Kong 2020-05-01 2021-04-30 NCT04346082, ONLINE-MIND Phase Not Applicable Not yet recruiting 1 12 Months 30 Kam Pui Lee, MSc, kam pui Lee, Msc 2020-04-16
A study to investigate the therapeutic benefit and safety of convalescent plasma in patients with Covid-19 Coronavirus disease 19 infection convalescent plasma alone Feinstein Institute for Medical Research, Mayo Clinic Foundation, Northwell Health Inc US Phase Not Applicable Planned 0 Craig Devoe, MD 2020-04-16
Compassionate Use Open-Label, Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection, Respiratory disease IC-14 alone Monocyte differentiation antigen CD14 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Implicit Bioscience Ltd Italy COV02, NCT04346277 Phase Not Applicable Recruiting 1 Lorenzo Dagna, MD 2020-04-17
ProCov: Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: A Pilot Study Coronavirus disease 19 infection prone positioning alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Intercommunal Aix-Pertuis France 2020-04-01 2020-05-01 20202703-2, NCT04344106, ProCov Phase Not Applicable Recruiting 1 1 Month 25 Camille begne, MD, Laurence Maulin, MD, Laurent Lefebvre, MD, Marie Bernardi, MD, Stephanie Martinez, MD, Thibaut Helbert, MD, Xavier ELHARRAR, Xavier ELHARRAR, MD, Youssef Trigui, MD 2020-04-17
Explore: Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19 Coronavirus disease 19 infection Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-01 Explore, FMASU P17A/ 2020, NCT04346056 Phase Not Applicable Not yet recruiting 1 7 Months 500 Sara Hassan Agwa 2020-04-17
Strain: To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database Coronavirus disease 19 infection Ion AmpliSeq alone, next-generation sequencing (NGS) alone, phylogenetic analysis alone, polymerase chain reaction (PCR) alone, reverse transcription polymerase chain reaction (rRT-PCR) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ain Shams University Egypt 2020-04-20 2020-12-01 FMASU P16A/ 2020, NCT04346043, Strain Phase Not Applicable Not yet recruiting 1 7 Months 100 Hesham Elghazaly,MD 2020-04-17
A serological testing study as a potential treatment for COVID-19 infection Coronavirus disease 19 infection EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits alone, EUROLabWorkstations alone Beaumont Health NCT04349202 Phase Not Applicable Status not specified 0 2020-04-16
COVIDOC: Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) University Hospital, Montpellier France 2020-04-10 2021-04-06 COVIDOC, NCT04345861, RECHMPL20_168 Phase 2/Phase 3 Clinical Not yet recruiting 1 11 Months 150 Jacques REYNES, MD PhD, Jacques REYNES, MD,PhD, jacques REYNES, MD, PhD 2020-04-17
Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus Coronavirus disease 19 infection, Insulin dependent diabetes, Non-insulin dependent diabetes tele-intervention alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Federal University of Rio Grande do Sul Brazil 2020-04-17 2020-08-30 2020241093, NCT04344210 Phase Not Applicable Recruiting 1 4 Months 149 2020-04-17
COVID-19 Plasma Collection Coronavirus disease 19 infection convalescent plasma collection alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Thomas Jefferson University US 2020-04-13 2021-04-12 20D.346, NCT04344015 Phase Not Applicable Recruiting 0 12 Months 2000 Julie Karp, MD, Mackenzie Kemp, MPH 2020-04-17
A randomized, double-blinded, placebo-controlled, phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) Coronavirus disease 19 infection Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Vector) alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CanSino Biologics Inc, Institute of Biotechnology the Academy of Military Medical Sciences PLA, Jiangsu Province Centers for Disease Control and Prevention Ministry of Science and Technology of the People´s Republic of China China 2020-04-12 2021-01-31 ChiCTR2000031781 Phase 2 Clinical Not yet recruiting 3 9 Months 500 Hou Lihua, Zhu Fengcai 2020-04-17
Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen Coronavirus disease 19 infection vazegepant alone CGRP receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Biohaven Pharmaceutical Holding Co Ltd 2020-04-30 2020-07-31 BHV3500-203, NCT04346615 Phase 2/Phase 3 Clinical Not yet recruiting 0 3 Months 120 2020-04-17
PHYSIO-COVID: Implementation of Physiotherapy on COVID-19 Patients in ICU Coronavirus disease 19 infection phsyiotherapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier Sociedad Española de Neumología y Cirugía Torácica, Societe française de kinésithérapie en réanimation Chile, Spain, Belgium, France, Argentina, Italy 2017-04-01 2022-12-01 NCT04347070, PHYSIO-COVID, RECHMPL20_0175 Phase Not Applicable Recruiting 6 68 Months 150 Gustavo Plotnikow, Gustavo Plotnikow, Physiotherapis, Roberto Martinez-Alejos, Roberto Martinez-Alejos, MD, PhD, roberto Martinez-Alejos, Physiotherapis 2020-04-17
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis? Coronavirus disease 19 infection tuberculin test alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assiut University Egypt 2020-04-11 2020-06-30 ASSIUTU12, NCT04347876 Phase Not Applicable Recruiting 1 2 Months 100 Aliae AR Mohamed Hussein, Aliae AR Mohamed-Hussein 2020-04-17
CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort Coronavirus disease 19 infection, Viral pneumonia eculizumab alone Complement C5 factor inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Assistance Publique Hopitaux de Paris 2020-04-30 2020-08-31 APHP200375-4, CORIMUNO19-ECU, NCT04346797 Phase 2 Clinical Not yet recruiting 0 4 Months 120 Régis Peffault de Latour, MD PhD 2020-04-17
Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit Acute stress disorder, Coronavirus disease 19 infection Raymond Poincare University Hospital Hôpital Cochin France 2020-04-15 2020-09-01 CSC19APR, NCT04346810 Phase Not Applicable Not yet recruiting 1 4 Months 100 Dominique Fletcher, MD, PhD, HARKOUK Hakim, Hakim Harkouk, M.D. 2020-04-18
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) Coronavirus disease 19 infection leronlimab alone CCR5 chemokine antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) CytoDyn Inc US 2020-04-15 2021-04-01 CD12_COVID-19, NCT04347239 Phase 2 Clinical Recruiting 0 11 Months 390 Kush Dhody, MBBS, MS, CCRA 2020-04-17
A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019 Coronavirus disease 19 infection standard treatment alone Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jilin University China 2020-02-01 2020-12-01 130004, NCT04346602 Phase Not Applicable Recruiting 1 10 Months 132 Bai ling Yan, Doctor, Dong Yang, Master 2020-04-17
An Open, Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone, mefloquine (Farmzashita) alone, Variable regimens including azithromycin , hydroxychloroquine , mefloquine (Farmzashita) , tocilizumab Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Burnasyan Federal Medical Biophysical Center Russian Federation 2020-04-08 2020-08-01 FL-01/20, NCT04347031 Phase 2 Clinical Recruiting 1 3 Months 320 Tatiana Astrelina, MD PhD,DSc. 2020-04-17
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients Coronavirus disease 19 infection cadi-05 alone, standard care therapy alone Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cadila Pharmaceuticals Ltd Council of Scientific and Industrial Research (India) India 2020-04-20 2020-07-30 CRSC20004, NCT04347174 Phase 2 Clinical Not yet recruiting 1 3 Months 40 Anil Avhad, MBBS, Sanjay Patel, MBBS 2020-04-18
CONEC: Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single-Center Over the Course of 12 Months Coronavirus disease 19 infection blood and urine analysis alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna Austria 2020-04-11 2021-04-11 1375/2020, CONEC, NCT04347694 Phase Not Applicable Not yet recruiting 1 12 Months 400 Thomas J Reiter, MD 2020-04-17
PHYSIO-COVID: Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-09-30 2020-A00957-32, 2020_32, NCT04347928, PHYSIO-COVID Phase Not Applicable Not yet recruiting 1 5 Months 15 Thibault Duburcq, MD 2020-04-17
TEACHCOVID: Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study Coronavirus disease 19 infection, Viral pneumonia Hydroxychloroquine alone, standard of care alone, Variable regimens including Hydroxychloroquine , azithromycin , ceftriaxone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires de Strasbourg 2020-05-01 2021-08-01 7783, NCT04347512, TEACHCOVID Phase 3 Clinical Not yet recruiting 0 15 Months 405 Loic Kassegne, MD 2020-04-17
The Randomized, Open, Phase II Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 Coronavirus disease 19 infection clevudine alone, hydroxychloroquine alone DNA polymerase inhibitor, Nucleoside reverse transcriptase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bukwang Pharmaceutical Co Ltd 2020-04-24 2020-12-31 BK-CLV-201, NCT04347915 Phase 2 Clinical Not yet recruiting 0 8 Months 60 Bukwang Bukwang 2020-04-17
A Prospective 'Universal' Observational Database for COVID-19 Coronavirus disease 19 infection Hackensack Meridian Health Cota Inc US 2020-03-27 2021-04-30 NCT04347993, PRO2020-0342 Phase Not Applicable Recruiting 0 13 Months 5000 Andrew Ip, MD, Brittany Sinclaire, Urszula Bednarz 2020-04-17
RAPID-19: Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19 Coronavirus disease 19 infection Covid-19 Antibody testing alone, Loop mediated isothermal amplification alone Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) Queens University of Belfast Belfast Health & Social Care Trust UK 2020-04-13 2020-10-13 282617, NCT04347408, RAPID-19 Phase Not Applicable Not yet recruiting 1 6 Months 150 Sharon Christie, PhD, Thomas Waterfield, BMBCh 2020-04-17
Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19 Coronavirus disease 19 infection favipiravir alone, standard of care treatment alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stanford University US 2020-04-30 2021-04-30 56032, NCT04346628 Phase 2 Clinical Not yet recruiting 0 12 Months 120 Study Team, Yvonne (Bonnie) A Maldonado, MD 2020-04-16
COVIDHLH: Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH Coronavirus disease 19 infection, Hemophagocytic lymphohistiocytosis, Macrophage activation syndrome, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Technical University of Munich Germany 2020-03-27 2020-08-31 161/20 S, COVIDHLH, NCT04347460 Phase Not Applicable Recruiting 1 5 Months 20 Christoph Schmaderer, M.D., Georg Lorenz, M.D., Philipp Moog, M.D. 2020-04-17
Multicenter, observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Tokyo Japan 2020-04-14 UMIN000040162 Phase Not Applicable Recruiting 1 1000 Ryota Niikura 2020-04-17
IMPACT: Impact of Antimalarials on Covid Infections in RAPPORT Coronavirus disease 19 infection, Rheumatoid arthritis B-cell depletor therapy alone, IL-17 blocker therapy alone, JAK kinase inhibitor therapy alone, T-cell c-stimulation inhibitor therapy alone, anti-IL-6 blocker therapy alone, anti-TNF inhibitor therapy alone, chloroquine alone, disease modifying anti-rheumatic drug therapy alone, hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alberta Canada 2020-04-15 2021-04-30 IMPACT, NCT04347798, PRO00100000 Phase Not Applicable Recruiting 1 12 Months 500 Stephanie O Keeling, MD, Walter P Maksymowych, MD 2020-04-17
PRoVENT-COVID: Paactice of Ventilation in COVID-19 Patients Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Academic Medical Center, University of Amsterdam Netherlands 2020-03-06 2020-08-31 NCT04346342, PROVENT-COVID, PRoVENT-COVID Phase Not Applicable Recruiting 19 5 Months 1000 Anissa Tsonas, MD, Anna Geke Algera, MD, Ary Serpa Neto, MD, PhD, Frederique Paulus, PhD, Marcus Schultz, MD, PhD, Michela Botta, Michela Botta, MD 2020-04-17
A phase III study of Actemra for the treatment of hospitalized patients with severe COVID-19 pneumonia Coronavirus disease 19 infection, Viral pneumonia tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Chugai Pharmaceutical Co Ltd Japan Phase 3 Clinical Planned 1 2020-04-16
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) Coronavirus disease 19 infection bone marrow-derived mesenchymal stem cells alone, conventional treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Guangzhou Institute Of Respiratory Disease Guangzhou 8th People's Hospital, Tongji Hospital, Huazhong University of Science and Technology China 2020-04-30 2020-12-31 NCT04346368, SC-2020-01 Phase 1/Phase 2 Clinical Not yet recruiting 1 8 Months 20 Ming Liu, MD, ShiYue Li, Shiyue Li, MD 2020-04-17
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome Coronavirus disease 19 infection, Systemic inflammatory response syndrome anti-IL-6-R antibody therapy alone, ventilation support alone Brugmann University Hospital Belgium 2020-03-20 2020-12-31 CHUB-IL6-COVID-19, NCT04346017 Phase Not Applicable Recruiting 1 9 Months 200 Carole Nagant, MD, Carole Nagant, PhD, Francis Corazza, Francis Corazza, MD, Patrick Stordeur, PhD 2020-04-17
DHYSCO: Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Coronavirus disease 19 infection, Respiratory distress syndrome standardized ventilatory management alone, dexamethasone plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Association Marie Lannelongue France 2020-04-30 2020-08-31 2037815010, DHYSCO, NCT04347980 Phase 3 Clinical Not yet recruiting 1 4 Months 122 Francois STEPHAN, MD, PhD, Lilia Lamrani 2020-04-16
RegCOVID19: Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry Coronavirus disease 19 infection Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL 2020-04-15 2021-01-01 IDI-REM-2020-1, NCT04347278, RegCOVID19 Phase Not Applicable Not yet recruiting 0 8 Months 100 LUCIA LAVIN ALCONERO, Phd, MARIA DEL MAR GARCIA SAIZ, MDPhD 2020-04-17
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients Coronavirus disease 19 infection convalescent plasma alone, supportive care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Institute of Liver and Biliary Sciences, India India 2020-04-14 2020-06-30 ILBS-COVID-02, NCT04346446 Phase 2 Clinical Recruiting 2 2 Months 20 Dr Meenu Bajpai, MD, Dr Shiv Kumar Sarin, DM, Dr Suresh Kumar, MD 2020-04-18
COVID-HEP: Preventing COVID-19 Complications With Low and High-dose Anticoagulation Blood clotting disorder, Coronavirus disease 19 infection, Thrombosis enoxaparin sodium alone, unfractionated heparin alone Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires De Geneve Switzerland 2020-04-14 2020-11-30 2020-00794, COVID-HEP, NCT04345848 Phase 3 Clinical Not yet recruiting 1 7 Months 200 Marc Blondon 2020-04-16
A phase I clinical study of 7HP-349 in healthy subjects for the potential treatment of COVID-19 infection Coronavirus disease 19 infection 7HP-349 alone CD11a agonist, CD49d agonist, ICAM-1 stimulator, Integrin agonist, Vascular cell adhesion protein 1 agonist Healthy volunteers accepted 7 Hills Pharma Llc US Phase 1 Clinical Not yet recruiting 0 2020-04-17
Effect of SARS-CoV-2 infection upon male reproductive system Coronavirus disease 19 infection Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shandong Provincial Hospital China 2020-04-09 2021-04-01 ChiCTR2000031779 Phase Not Applicable Not yet recruiting 1 11 Months 50 Liqiang Guo, Shengtian Zhao 2020-04-17
PEACE: Post-exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With Choloroquine Compounds Coronavirus disease 19 infection hydroxychloroquine sulfate alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Specialized Healthcare and Medical Education Department Forman Christian College, Harvard TH Chan School of Public Health, Mayo Hospital, Pakistan Kidney and Liver Institute, SERVICES INSTITUTE OF MEDICAL SCIENCES US 2020-04-14 2021-05-28 NBC-COVID19-02, NCT04346667, PEACE Phase 4 Clinical Not yet recruiting 0 13 Months 400 Ammar Sarwar, Ammar Sarwar, MD 2020-04-17
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease Coronavirus disease 19 infection RT-PCR test alone, artificial intelligence technology deep learning method alone, computed tomography imaging alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Xinqiao Hospital of Chongqing China 2020-01-17 2020-05-31 NCT04347369, XQONC-015 Phase Not Applicable Recruiting 1 4 Months 1000 Jianguo Sun, Sun JG 2020-04-16
Predict Adverse Events by Covid-19 Nephritis Coronavirus disease 19 infection, Nephritis urine analysis alone Healthy volunteers accepted University Hospital Goettingen Transplantationszentrum Köln-Merheim, University Hospital, Aachen, Universitätsklinikum Hamburg-Eppendorf Germany 2020-04-13 2021-12-31 NCT04347824, UMG_CO19-NEPHRITIS Phase Not Applicable Not yet recruiting 1 20 Months 100 Oliver Gross, MD, Prof. Dr. O. Gross 2020-04-17
Chloroquine UN: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National University of Colombia Fundacion Salud de los Andes Colombia 2020-04-20 2020-10-01 Chloroquine UN, NCT04346329, UNAL-COVID-CP Phase 3 Clinical Not yet recruiting 2 5 Months 86 Calos A Parra-Lopez, MD PhD, Carlos A Parra-López, MD, PhD, Carlos A parra-Lopez, MD PhD, Carlos Alberto Parra Lopez, David A Bernal-Estevez, MD PhD, David A Bernal-Estévez, MD, PhDc 2020-04-17
Safety and Efficacy of Ruxolitinib for COVID-19 Coronavirus disease 19 infection, Viral pneumonia ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Colorado, Denver, US US 2020-04-30 2020-10-31 20-0869, NCT04348071 Phase 2/Phase 3 Clinical Not yet recruiting 0 6 Months 80 Angela Rachubinski, PhD, Joaquin Espinosa, PhD, Joaquin M Espinosa, PhD 2020-04-18
Prophylactic Hydroxychloroquine versus Vitamin C in Healthcare Workers: RCT Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stony Brook University Hospital US 2020-04-20 2020-12-30 IRB2020-00222, NCT04347889 Phase 2 Clinical Not yet recruiting 0 8 Months 1212 Adam Singer 2020-04-16
COVIDotheque: A Cohort of Patients With Possible or Confirmed SARS-CoV-2(COVID-19) Coronavirus disease 19 infection blood sampling alone Healthy volunteers accepted University Hospital, Montpellier France 2020-02-01 2022-12-30 COVIDotheque, NCT04347850, RECHMPL20_0185 Phase Not Applicable Recruiting 1 34 Months 500 Edouard TUAILLON, MD, PhD 2020-04-17
Phase II, randomized, placebo-controlled, double-blind, single-center study evaluating the safety and efficacy of adipose-derived mesenchymal stem cells (HB-adMSCs) in COVID-19 patients Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Hope Biosciences Inc Phase 2 Clinical Not yet recruiting 0 100 2020-04-17
A clinical trial of ADX-629 for the treatment of patients with COVID-19-associated respiratory disease Coronavirus disease 19 infection, Respiratory distress syndrome ADX-629 alone Acetaldehyde dehydrogenase inhibitor Aldeyra Therapeutics Inc Phase Not Applicable Planned 0 2020-04-16
Spironolactone in Covid-19 Induced ARDS Coronavirus disease 19 infection, Respiratory distress syndrome spironolactone alone Aldosterone antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istanbul University-Cerrahpasa Turkey 2020-04-21 2020-10-21 10042020, NCT04345887 Phase 4 Clinical Not yet recruiting 1 6 Months 60 Olcay Dilken, Yalim Dikmen 2020-04-17
CoVid-19 - Infection and Antibody Formation in the Viennese Population Coronavirus disease 19 infection serum blood and antibody measurement alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ludwig Boltzmann Institute for Lung Vascular Research Austria 2020-04-27 2020-09-30 LEAD COVID-19, NCT04346264 Phase Not Applicable Recruiting 1 5 Months 5500 Otto C Burghuber, Prof.MD 2020-04-17
Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19 Coronavirus disease 19 infection, Hypoxia double-trunk mask alone, standard nasal cannula alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Clinique Universitaires Saint-Luc, Universite Catholique de Louvain Belgium 2020-04-09 2020-06-30 DTM-001, NCT04346420 Phase Not Applicable Recruiting 1 2 Months 15 Poncin, William Poncin, William Poncin, PT, PhD 2020-04-17
WUHAN: Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT Coronavirus disease 19 infection standard medical care alone, black cumin plus honey Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Federal Postgraduate Medical Institute Mayo Hospital Pakistan 2020-04-15 2020-05-30 1.6/M.EDU/141/2020, NCT04347382, WUHAN Phase 3 Clinical Recruiting 1 1 Month 30 Ahmad Imran, MBBS, Ayesha Hamayun, PhD, Muhammad Ahmad Imran, MBBS, Muhammad Ashraf, PhD, Shoaib Ashraf, PhD, Sohaib Ashraf, MBBS 2020-04-17
CALAVI: Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus) Coronavirus disease 19 infection Best Supportive Care alone, acalabrutinib alone Btk tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) AstraZeneca plc Acerta Pharma BV US, Europe 2020-12-18 2022-01-28 ACE-ID-201, CALAVI, D822FC00001, NCT04346199 Phase 2 Clinical Not yet recruiting 0 13 Months 428 AstraZeneca Cancer Study Locator, AstraZeneca Clinical Study Information Center, Louis M. Staudt, Wyndham H. Wilson 2020-04-17
A Study to Assess the Virus, RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease Conjunctivitis, Coronavirus disease 19 infection, Inflammatory disease Schirmer Test I alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universita Degli Studi G D`Annunzio Chieti Italy 2020-04-14 2020-04-30 NCT04346160, UCHIETI03 Phase Not Applicable Not yet recruiting 1 25 Leonardo Mastropasqua, Leonardo Mastropasqua, Professor, Manuela Lanzini, Doctor 2020-04-17
COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff Coronavirus disease 19 infection Elisa-test for IgM and IgG alone, IgM and IgG diagnostic kits test alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Herlev Hospital Region Hovedstaden HS Hvidovre Hospital, Mental Health Services in the Capital Region of Denmark, Nordsjaellands Hospital, Rigshospitalet, Denmark, University Hospital Bispebjerg and Frederiksberg Denmark 2020-04-15 2021-08-01 NCT04346186, REGHCOVIDSCREENING Phase 4 Clinical Not yet recruiting 14 15 Months 30000 Curt Sten, Fredrik Folke, Associate prof., Henning Bundgaard, Prof., Henrik Ullum, Prof., Ida Hageman, Jørgen Rungby, Jørgen Rungby, Prof., Kasper Iversen, Kasper Iversen, Prof., Ove Andersen, Prof., Rasmus Hasselbalch, Rasmus Hasselbalch, MD, Susanne Dam Poulsen, Prof., Thea Kølsen Fischer, Thomas Benfield, Prof. 2020-04-17
SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with moderate COVID-19 Coronavirus disease 19 infection remdesivir alone RNA polymerase modulator Gilead Sciences Inc 2020-04-14 SIMPLE Phase 3 Clinical Recruiting 0 2020-04-16
SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with severe COVID-19 Coronavirus disease 19 infection remdesivir alone RNA polymerase modulator Gilead Sciences Inc 2020-04-14 SIMPLE Phase 3 Clinical Recruiting 0 2020-04-16
MACOVIA: A phase II/III, double-blinded, randomized, placebo-controlled, multicenter, pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate to severe acute respiratory distress syndrome (ARDS) induced by the novel coronavirus disease (COVID-19) Coronavirus disease 19 infection, Respiratory distress syndrome multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases), Athersys/ Healios alone Athersys Inc US 2020-06-30 MACOVIA Phase 2/Phase 3 Clinical Not yet recruiting 0 400 2020-04-17
A randomized-controlled, double-blind study to evaluate the effectiveness of the Kerecis Omega3 Viruxide system in COVID-19 patients Coronavirus disease 19 infection Kerecis Omega3 Viruxide system alone Kerecis Ehf Phase Not Applicable Status not specified 0 2020-04-16
Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 Advanced solid tumor, Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia BMS-986253 alone IL-8 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Columbia University Bristol-Myers Squibb Co US 2020-04-30 2022-09-30 AAAS9881, NCT04347226 Phase 2 Clinical Not yet recruiting 0 29 Months 138 Lisa Olmos, RN, Matthew Dallos, MD 2020-04-17
ProCoV: Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany Coronavirus disease 19 infection serological examination alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Krankenhaus Reinbek St. Adolf-Stift Germany 2020-04-14 038/20 I, DRKS00021270, ProCoV Phase Not Applicable Not yet recruiting 1 800 Jonas Herzberg, Tim Strate 2020-04-17
A randomized, placebo-controlled, phase II study to assess the effect of fenretinide in patients with Covid-19 Coronavirus disease 19 infection, Lung inflammation fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University/Laurent Pharmaceuticals alone Nuclear factor kappa B gene modulator Laurent Pharmaceuticals US, Canada Phase 2 Clinical Planned 1 200 2020-04-17
A clinical trial of baricitinib for the potential treatment of hospitalized patients diagnosed with COVID-19 Coronavirus disease 19 infection baricitinib alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Eli Lilly & Co National Institute of Allergy and Infectious Diseases Phase Not Applicable Planned 0 2020-04-17
A Study to Assess the Effect of SoftWaves in Patients with Covid-19 Coronavirus disease 19 infection SoftWaves alone Tissue Regeneration Technologies Llc Phase Not Applicable Recruiting 0 2020-04-16
A clinical trial to evaluate the effectiveness of different combinations of the anti-malarial drugs chloroquine and hydroxychloroquine and azithromycin in treating ill patients infected with the novel coronavirus Coronavirus disease 19 infection chloroquine alone, hydroxychloroquine alone, Variable regimens including azithromycin , chloroquine , hydroxychloroquine Washington University in St Louis Barnes-Jewish Hospital Foundation, National Center For Advancing Translational Sciences US Phase Not Applicable Status not specified 0 500 Jane O’Halloran, Rachel M. Presti 2020-04-16
A phase I clinical trial of S-protein COVID antigen vaccine for the prevention of COVID-19 infection Coronavirus disease 19 infection protein subunit vaccine (COVID-19), Sanofi Pasteur alone GlaxoSmithKline plc, Sanofi Pasteur, Sanofi SA 2020-12-31 Phase 1 Clinical Planned 0 2020-04-16
An questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19) infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia hydroxychloroquine alone The Second XiangYa Hospital of Central South University Hunan Provincial Department of Finance China 2020-04-10 2020-06-30 ChiCTR2000031782 Phase Not Applicable Not yet recruiting 1 2 Months 1200 Hui Jin, Qianjin Lu 2020-04-17
Investigation for Prevention Awareness against COVID-19 Coronavirus disease 19 infection, Viral pneumonia Male, Adolescents (13-17 yrs), Young Adults (18-44 yrs) Universitad Major de S. Andres,, Wuhan University Bolivia 2020-03-17 ChiCTR2000031783 Phase Not Applicable No longer recruiting 1 883 DIANA MARIA CESPEDES ARCANI 2020-04-17
A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The Central Hospital of Huanggang China 2020-04-08 2020-05-08 ChiCTR2000031794 Phase Not Applicable Not yet recruiting 1 1 Month 130 Liping Jia, Quanshui Hao 2020-04-17
Evaluation of Hydroxychloroquine for prevention of hospitalization and respiratory complications in patients with confirmed diagnosis or suspected infection by (COVID-19) Coronavirus disease 19 infection, Respiratory disease hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) EMS SA, Hospital Alemao Oswaldo Cruz Brazil 2020-04-10 2020-07-10 A27736297878, RBR-3cbs3w Phase 3 Clinical Not yet recruiting 1 3 Months 1300 Dayane Correa Vila Nova, Priscila Kazue Kunitake, Álvaro Avezum 2020-04-17
Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes Coronavirus disease 19 infection, Lung disease Non-specific Toning Exercise Program alone, Respiratory Exercise Program alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Universidad de Sevilla Spain 2020-04-01 2020-04-15 ET-SEF-21/20, RBR-6m69fc Phase Not Applicable Recruiting 1 99 Carlos Bernal Utrera 2020-04-17
A clinical study of GV-1001 to treat COVID-19 patients Coronavirus disease 19 infection tertomotide alone Telomerase modulator GemVax & Kael Co Ltd South Korea Phase Not Applicable Not yet recruiting 1 2 2020-04-15
A clinical study of Cellgram-AKI, a stem cell therapy, for the treatment of COVID-19 patients Coronavirus disease 19 infection Cellgram-AKI alone FCB-Pharmicell Co Ltd South Korea Phase Not Applicable Not yet recruiting 1 24 2020-04-15
CoVitTrial: Covid-19 and Vitamin D Supplementation: a Multicenter, Randomized, Controlled Trial of High-Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients Coronavirus disease 19 infection, Viral pneumonia Zymad alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers Mylan Laboratories Ltd France 2020-04-30 2020-07-31 2020-001602-34, CoVitTrial, NCT04344041 Phase 3 Clinical Not yet recruiting 9 3 Months 260 Achille TCHALLA, Bertrand FOUGERE, Claire ROUBAUD BAUDRON, Cédric ANNWEILER, DCRI Angers, Frédéric SHOLASTIQUE, Guillaume CHAPELET, Jean Baptiste BEUSCART, Marjorie HOUVET, Olivier GUERIN, Thomas CELARIER 2020-04-16
Angiotensin Converting Enzyme Inhibitors in Treatment of COVID-19 Coronavirus disease 19 infection Variable regimens including captopril , chloroquine , enalapril ACE inhibitor Tanta University Egypt 2020-04-15 2029-12-01 ACEIS COVID 19, NCT04345406 Phase 3 Clinical Not yet recruiting 1 115 Months 60 Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. 2020-04-16
Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health Coronavirus disease 19 infection Healthy volunteers accepted Assiut University Egypt 2020-05-31 2020-10-31 COVID-19 MENTAL HEALTH, NCT04344834 Phase Not Applicable Not yet recruiting 1 5 Months 300 Haidi Karam 2020-04-16
CovidRegOUH: Prospective Quality Register of Patients With Confirmed COVID-19 at Oslo University Hospital Coronavirus disease 19 infection Oslo University Hospital Norway 2020-03-15 2021-05-01 COVIDREGOUH, CovidRegOUH, NCT04345536 Phase Not Applicable Recruiting 1 13 Months 400 Aleksander Holten, MD, Aleksander Holten, PhD, Aleksander Rygh Holten, Kristian Tonby, MD 2020-04-16
CYTOCOV-19: Effect of CytoSorb Adsorber on Hemodynamical and Immunological Parameters in Critical Ill Patients With COVID-19 Coronavirus disease 19 infection CytoSorb adsorber alone, hemoadsorption alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitätsklinikum Hamburg-Eppendorf Germany 2020-04-01 2021-02-28 CYTOCOV-19, CYTOCOV-19, DRKS00021199, NCT04344080, U1111-1250-2078 Phase Not Applicable Recruiting 1 11 Months 24 Axel Nierhaus, MD, Dominik Jarczak, MD, Kevin Roedl, MD, Stefan Kluge, MD 2020-04-17
ChilblainCOVID: Assessment of Chilbains Occuring During Covid-19 Infection Coronavirus disease 19 infection, Dermatological disease Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Nice France 2020-04-09 2020-06-30 20DERMATOCOVID.02, ChilblainCOVID, NCT04344119 Phase Not Applicable Recruiting 1 2 Months 30 Cynthia CAILLON, Sylvie MALERBA, Thierry PASSERON 2020-04-17
PISCO: Pyridostigmine in Severe SARS-CoV-2 Infection Coronavirus disease 19 infection, Viral pneumonia Mestinon alone, medical care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Ciencias Medicas y Nutricion Mexico 2020-04-04 2021-04-30 INF-3323, NCT04343963, PISCO Phase 2/Phase 3 Clinical Recruiting 1 12 Months 436 José C Crispín, MD, PhD, Juan Sierra-Madero, MD, Sergio I Valdés-Ferrer, MD, PhD 2020-04-16
Covid-19, Case-Cluster Study Coronavirus disease 19 infection Healthy volunteers accepted University of Bonn Ministerium für Arbeit, Gesundheit und Soziales NRW Germany 2020-03-31 DRKS00021306, Lfd. Nr. 085/20 Phase Not Applicable Recruiting 1 1400 Hendrik Streeck 2020-04-15
EVICT-CORONA-ALI: Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury Acute lung injury, Coronavirus disease 19 infection, Hypoxia vitamin C alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Virginia Commonwealth University US 2020-04-22 2021-05-31 EVICT-CORONA-ALI, HM20018977, NCT04344184 Phase 2 Clinical Not yet recruiting 0 13 Months 200 Alpha (Berry) A Fowler, III, MD, Brian Davis, MD, Markos G Kashiouris, MD MPH 2020-04-15
Gargling and Nasal Rinses to Reduce Oro and Nasopharyngeal Viral Load in Patients With COVID-19 Coronavirus disease 19 infection chlorhexidine gluconate alone, povidone-iodine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) NYU Langone Health US 2020-04-09 2020-05-09 NCT04344236, S20-00444 Phase 2 Clinical Recruiting 0 1 Month 48 Lindsey Moses, MD, Scott Rickert, Scott Rickert, MD 2020-04-15
OHB10cov: Management by Hyperbaric Oxygen Therapy of Patients With Hypoxemic Pneumonia With SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection, Viral pneumonia hyperbaric chamber alone, hyperbaric oxygen plus normobaric oxygen Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Direction Centrale du Service de Sante des Armees France 2020-04-30 2021-05-31 2020PPRC03, NCT04344431, OHB10cov Phase 2/Phase 3 Clinical Not yet recruiting 1 13 Months 100 Jean-Eric BLATTEAU, MD, PhD 2020-04-16
APCOLIS STUDY: The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver Coronavirus disease 19 infection, Hepatitis, Liver cirrhosis, Liver disease Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Institute of Liver and Biliary Sciences, India India 2020-04-14 2020-06-30 APCOLIS STUDY, ILBS-COVID-01, NCT04345640 Phase Not Applicable Recruiting 1 2 Months 100 Dr Ashok Choudhary, DM, Dr Shiv Kumar Sarin, DM 2020-04-16
CORIMMUNO-COAG: Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Coronavirus disease 19 infection, Lung disease heparin sodium Choay alone, nadroparin calcium alone, tinzaparin sodium alone Antithrombin III, Factor Xa antagonist, Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-20 2020-09-30 APHP200389-6, CORIMMUNO-COAG, NCT04344756 Phase 2 Clinical Not yet recruiting 3 5 Months 808 Damien Roux, MD PhD, Frédéric Penne, MD PhD, Jean-Luc Diehl, Tristan Mirault 2020-04-16
Effect of Trifluoperazine in treatment of COVID-19 Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , lopinavir + ritonavir , ribavirin , trifluoperazine HIV protease inhibitor Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Birjand University Iran 2020-04-16 IR.BUMS.REC.1399.004, IRCT20200408046992N1 Phase 3 Clinical Recruiting 1 70 Dr Masood Ziaee, Kazem Dastjerdi, Masood Ziaee, Motahareh Mahi-Birjand 2020-04-17
RCT: Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease Coronavirus disease 19 infection hydroxychloroquine alone, azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) LCMC Health US 2020-04-10 2021-12-10 COVID 2020-001, NCT04344444, RCT Phase 3 Clinical Recruiting 0 20 Months 600 Jeannine Ascani, Jeannine Ascani, MS, Meredith Clement, MD 2020-04-16
CovidDB: The Covid-19 Inpatient Database Coronavirus disease 19 infection ClarData Romania, Germany 2020-03-30 2023-06-30 COVIDDB, CovidDB, NCT04344171 Phase Not Applicable Recruiting 4 39 Months 5000 Julia Ferencz, MD, Marius Ghidau, Dr., Ovidiu Bedreag, Prof., Sebastian Dieng, Thomas Seufferlein, Prof. 2020-04-16
Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Coronavirus disease 19 infection, Viral pneumonia danoprevir plus ritonavir Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Wuhan Huoshenshan Hospital Ascletis Pharmaceutical Co Ltd China 2020-03-18 2020-05-31 ASC-CTP-HS-01, ChiCTR2000031734, NCT04345276 Phase 4 Clinical Recruiting 1 2 Months 40 Bo Wei, MD, Junxue Wang, MD, Yahong Chen, MD 2020-04-17
Phase I/II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia Coronavirus disease 19 infection natural killer cell alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) National University of Colombia Fundacion Salud de los Andes Colombia 2020-04-13 2020-11-10 NCT04344548, UNAL FSA COVID Phase 1/Phase 2 Clinical Not yet recruiting 2 6 Months 10 Carlos A Parra-Lopez, MD PhS, Carlos Alberto Parra Lopez, David A Bernal E., MD PhD, David A Bernal-Estévez, MD PhD, Doris Mejía 2020-04-17
NIAID: COVID-19 Plasma Collection Coronavirus disease 19 infection plasma collection alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) National Institutes of Health Clinical Center US 2020-04-15 2025-04-01 200081, NCT04344977, NIAID Phase Not Applicable Not yet recruiting 0 59 Months 2800 2020-04-17
CORIMUNO-19-BEVA: Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zirabev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Coronavirus disease 19 infection bevacizumab alone, bevacizumab biosimilar, Pfizer alone VEGF ligand inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris 2020-04-15 2020-11-30 APHP200389-7, CORIMUNO-19-BEVA, NCT04344782 Phase 2 Clinical Not yet recruiting 0 7 Months 130 Jacques Cadranel, MD PhD 2020-04-18
A Study to Assess the Effect of Allocetra in Patients with COVID-19 Coronavirus disease 19 infection Allocetra alone Enlivex Therapeutics Ltd Israeli Government Israel Phase Not Applicable Not yet recruiting 1 2020-04-15
COVIDICUS: Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia Airvo-2, Fisher and Paykel Healthcare alone, continuous positive airway pressure (CPAP) alone, conventional oxygen therapy alone, dexamethasone alone, high-flow-nasal cannula alone, mechanical ventilation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-10 2020-12-31 2020-001457-43, APHP200388, COVIDICUS, NCT04344730 Phase 2 Clinical Recruiting 1 8 Months 550 Jean François TIMSIT, Pr, Jean-François TIMSIT, Pr, LILA BOUADMA, Pr, Lila Bouadma, Pr 2020-04-16
A Study of CM-4620 Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia CM-4620 alone Ca2+ release activated Ca2+ channel 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CalciMedica Inc US 2020-04-08 2020-09-30 CM4620-204, NCT04345614 Phase 2 Clinical Recruiting 0 5 Months 60 Charles Bruen, MD, Joseph Miller, MD, Kathleen Wilson, RN, Ken Stauderman, PhD, Marissa K. Peterson, Sudarshan Hebbar, MD 2020-04-16
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers Coronavirus disease 19 infection hydroxychloroquine sulfate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hackensack Meridian Health US 2020-04-14 2022-04-08 NCT04345653, PRO2020-0356 Phase 2 Clinical Recruiting 0 23 Months 45 Jawad Kirmani, MD 2020-04-17
Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients Coronavirus disease 19 infection, Viral pneumonia bacterial species isolation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation France 2020-04-30 2020-12-31 NCT04344509, PAVM COVID Phase Not Applicable Not yet recruiting 1 8 Months 10000 Christophe BURUCOA 2020-04-16
A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Dyspnea, Viral pneumonia exercise rehabilitation under remote monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Jiangsu Provincial People’s Hospital CF PharmTech Inc China 2020-04-20 2020-10-20 ChiCTR2000031834 Phase Not Applicable Not yet recruiting 2 6 Months 120 Li Jianan, Wang Wenxia 2020-04-16
Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universite Libre de Bruxelles Belgium 2020-04-15 2020-07-15 NCT04344145, PSY-ENCOVID19 Phase Not Applicable Not yet recruiting 1 3 Months 200 Andrée Marcoen, Julien Tiete, PhD 2020-04-16
A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia The First People's Hospital of Jingzhou National Natural Science Foundation of China China 2020-02-01 2020-12-31 ChiCTR2000031836 Phase Not Applicable No longer recruiting 1 11 Months 45 Jinzhi Lu 2020-04-16
A Real-life Experience on Treatment of Patients With COVID 19 Coronavirus disease 19 infection Alexoquine alone, Yomesan alone, favipiravir alone, ivermectin alone, nitazoxanide alone, Alexoquine plus azithromycin Chloride channel modulator, RNA polymerase inhibitor Tanta University Egypt 2020-04-15 2029-12-31 COVID 19 TREATMENT, NCT04345419 Phase 2/Phase 3 Clinical Not yet recruiting 1 116 Months 100 Eslam Saber, ass. lect, Mai Khalaf, ass. lect., Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. 2020-04-16
Covid-19 Pandemic. Emerging Legal and Ethical Disputes Over Patient Confidentiality Coronavirus disease 19 infection questionnaire alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Assiut University Egypt 2020-04-30 2020-07-31 2020A10, NCT04344938 Phase Not Applicable Not yet recruiting 1 3 Months 874 Noha Esmael Ebrahem, 2020-04-18
Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia rehabilitation exercise alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Beijing Sport Uninversity China 2020-04-27 2020-09-16 ChiCTR2000031860 Phase 0 Clinical Not yet recruiting 1 4 Months 150 Jinghua Qian, Zicheng Gao 2020-04-16
COVI-GAPP: Can the Ava fertility tracker device detect early signs of COVID-19? Coronavirus disease 19 infection AVA bracelet alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Lab Medical Center Dr. Risch AG Government of the Principality of Liechtenstein, HANELA-Stiftung, House of Liechtenstein Liechtenstein 2020-03-20 2021-12-31 1.2, COVI-GAPP, ISRCTN51255782 Phase Not Applicable Recruiting 1 21 Months 7170 Dr Martin Risch, Dr Stefanie Aeschbacher, Mrs Kirsten Grossmann, Prof David Conen, Prof Risch 2020-04-17
Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia natural killer (NK) cells from umbilical cord blood alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Huzhou Central Hospital Huzhou Science and Technology Bureau China 2020-03-01 2021-02-28 ChiCTR2000031735 Phase 0 Clinical Not yet recruiting 1 12 Months 20 Enhai Cui, Feng Hua 2020-04-16
Anti COVID-19 Convalescent Plasma Therapy Coronavirus disease 19 infection anti-SARS-CoV-2 convalescent plasma alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) OrthoSera Korlátolt Felelősségű Társaság Hungarian National Blood Service, Semmelweis University, University Of Pécs Hungary 2020-04-14 2021-04-01 ANTICOVID19ORT, NCT04345679 Phase 0 Clinical Not yet recruiting 1 11 Months 20 Eszter Fodor, medical doctor, Veronika Müller, MD, PhD, Zsombor Lacza, MD, PhD 2020-04-16
Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function Coronavirus disease 19 infection, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Puai Hospital China 2020-04-01 2022-04-01 ChiCTR2000031751 Phase Not Applicable Recruiting 1 24 Months 90 zhu pengfei 2020-04-16
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Coronavirus disease 19 infection, Respiratory distress syndrome mesenchymal stromal cells alone, Tylenol plus cetirizine Histamine H1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Baylor College of Medicine Center for Cell and Gene Therapy, Houston Methodist US 2020-05-31 2022-02-28 H-47561 MSC FOR COVID-19, NCT04345601 Phase 0 Clinical Not yet recruiting 0 21 Months 30 LaQuisa Hill, MD 2020-04-16
HEROs: Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus? Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University Health Network Canadian Institutes of Health Research, National Research Council of Canada Canada 2020-03-29 2022-01-30 HEROS PROTOCOL 1.1, HEROs, ISRCTN14326006 Phase 2 Clinical Recruiting 6 22 Months 988 Dr Julie Wright, Dr Kevin Kain, Dr Megan Landes 2020-04-16
COVER: The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study) Coronavirus disease 19 infection, Vascular disease University Hospitals Coventry & Warwickshire NHS Trust National Institute for Health Research (NIHR) Yemen, South Africa, Cameroon, Czech Republic, Germany, Denmark, Eritrea, Spain, Faroe Islands, Grenada, Niue, New Zealand, Peru, Palau, Singapore, Saint Helena, Slovakia, Senegal, Trinidad and Tobago, Tanzania, Uruguay, Mayotte, Mongolia, Mauritania, Afghanistan, Bosnia and Herzegovina, Barbados, Burundi, Cape Verde, Hong Kong, Hungary, Saint Kitts and Nevis, Latvia, Mali, Dominica, Cocos (Keeling) Islands, Ethiopia, UK, French Guiana, Guadeloupe, Equatorial Guinea, Nigeria, Qatar, Suriname, Sao Tome and Principe, Syria, Thailand, Uzbekistan, New Caledonia, Andorra, Armenia, Australia, Burkina Faso, Bouvet Island, Switzerland, Estonia, Finland, Falkland Islands, Gabon, Norfolk Island, Panama, Palestine, Somalia, Saint Vincent and the Grenadines, Vietnam, Samoa, Greece, Israel, Jamaica, Kazakhstan, Kuwait, Sri Lanka, Montenegro, Marshall Islands, Maldives, Malaysia, Guatemala, Heard Island and McDonald Islands, Haiti, Kenya, Laos, Lebanon, Madagascar, Macedonia, The Former Yugoslav Republic of, Martinique, Mauritius, Malawi, Argentina, Bangladesh, Chile, Costa Rica, Dominican Republic, Egypt, France, Ghana, Saint Pierre and Miquelon, Saudi Arabia, Sudan, Togo, Turkey, Venezuela, Vanuatu, Wallis and Futuna, Zambia, Honduras, Iran, Cambodia, Saint Lucia, Indonesia, Iceland, Jordan, Comoros, South Korea, Cayman Islands, Lesotho, Luxembourg, American Samoa, Bulgaria, Bahrain, Benin, Bolivia, Ivory Coast, Christmas Island, Cyprus, Central African Republic, Gibraltar, Norway, Oman, Pakistan, Romania, Sweden, San Marino, Turks and Caicos Islands, Tunisia, Tonga, Tuvalu, United States Minor Outlying Islands, Chad, Timor-Leste, Turkmenistan, El Salvador, Zimbabwe, Croatia, Isle of Man, Jersey, Japan, Kiribati, Libya, Morocco, Northern Mariana Islands, Montserrat, Namibia, Antigua and Barbuda, Albania, Azerbaijan, Bahamas, Bhutan, Cook Islands, China, Cuba, Belize, Ecuador, Western Sahara, Fiji, Georgia, Guinea, Poland, Pitcairn, Serbia, Seychelles, Svalbard and Jan Mayen, Swaziland, French Southern Territories, Uganda, Anguilla, Aruba, Bermuda, Belarus, Congo, Colombia, Guam, Ireland, India, Liberia, Moldova, Republic of, Malta, Netherlands Antilles, Angola, Antarctica, Austria, Belgium, Brunei, Botswana, Djibouti, Algeria, Canada, Nepal, Papua New Guinea, Philippines, Paraguay, Saint Barthelemy, Russian Federation, Rwanda, Solomon Islands, Sierra Leone, Tajikistan, Tokelau, Taiwan, Ukraine, US, Virgin Islands, Guyana, Guinea-Bissau, British Indian Ocean Territory, Iraq, Italy, Kyrgyzstan, Liechtenstein, Lithuania, Monaco, Burma, Mexico, Mozambique, Niger, United Arab Emirates, Brazil, Guernsey, Greenland, Gambia, Netherlands, Nicaragua, Nauru, French Polynesia, Puerto Rico, Portugal, Slovenia 2020-03-23 2022-04-01 COVER, COVER_01, IRAS 282224, ISRCTN80453162 Phase Not Applicable Recruiting 234 24 Months Athanasios Saratzis, Prof Christopher Imray, Ruth Benson, Sandip Nandhra 2020-04-16
ConPlas-19: Convalescent Plasma Therapy Versus SOC for the Treatment of COVID-19 in Hospitalized Patients Coronavirus disease 19 infection Variable regimens including chloroquine , convalescent plasma , darunavir + cobicistat , hydroxychloroquine , lopinavir + ritonavir , tocilizumab HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Puerta de Hierro Majadahonda Spain 2020-04-03 2020-07-31 CONPLAS-19, ConPlas-19, NCT04345523 Phase 2 Clinical Recruiting 9 3 Months 278 Antonio Ramos, MD, PhD, Cristina Avendaño Solá, Cristina Avendaño Solá, MD, PhD, Cristina Hernández Guitiérrez, MD, Cristina Hernández Gutiérrez, MD, Elena Flores Ballester, MD, Elena Muñez, MD, PhD, Gemma Moreno, MD, Ignacio de Santos Gil, MD, Inmaculada Casas Flecha, PharmD, PhD, Isabel Vicuña Andrés, MD, Jaime Lora Tamayo, MD, Javier Anguita Velasco, MD, Javier Martínez Sanz, MD, José Antonio Moreno Chulilla, MD, PhD, José Luis Bueno, MD, José Ramón Paño Pardo, MD, PhD, Margarita Barberana, MD, Marina Machado, MD, María Isabel Saez Serrano, MD, María Liz Paciello, MD, Miguel Cervero Jiménez, MD, Rafael Duarte Palomino, MD, PhD, Vicente Estrada Pérez, MD 2020-04-16
COVCALL: Prevalence of COVID-19 Symptoms History in Patients With Autoimmune Diseases Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fondation Ophtalmologique Adolf De Rothschild France 2020-04-30 2020-10-31 COVCALL, GDE_2020_11, NCT04345159 Phase Not Applicable Not yet recruiting 1 6 Months 1500 Amélie YAVCHITZ, MD, Damien GATINEL, MD, Guillaume DEBELLEMANIERE, MD 2020-04-16
CCU-COVID19: Impact of COVID19 Outbreak in Cardiac Acute Care Cardiac failure, Coronavirus disease 19 infection CT scan alone, RT-PCR alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris Action, France France 2020-03-20 2020-08-31 CCU-COVID19, INDS 0522070420, NCT04344912 Phase Not Applicable Recruiting 1 5 Months 500 Gilles MONTALESCOT, MD PhD, Johanne SILVAIN, MD PhD 2020-04-16
PROTECT: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection Coronavirus disease 19 infection peginterferon lambda-1a, Eiger BioPharmaceuticals alone Interferon receptor modulator, Interleukin-29 ligand Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Johns Hopkins University Eiger BioPharmaceuticals Inc US 2020-04-30 2021-06-30 IRB00248163, NCT04344600, PROTECT Phase 2b Clinical Not yet recruiting 0 14 Months 164 Mark Sulkowski, MD, Stephanie Katz, BSN 2020-04-16
Effect of Intravenous vitamin c in Patients with COVID-19 Coronavirus disease 19 infection Variable regimens including atazanavir + ritonavir , hydroxychloroquine , vitamin C Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-18 IR.TUMS.VCR.REC.1399.078, IRCT20200411047025N1 Phase 2/Phase 3 Clinical Not yet recruiting 1 110 Besharat Zarezade, Fereshteh Ghiasvand 2020-04-16
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalized COVID-19 Patients With High Risk of Progression Coronavirus disease 19 infection, Viral pneumonia tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Malaya Malaysia 2020-04-15 2020-10-31 NCT04345445, TVCS-COVID19 Phase 3 Clinical Not yet recruiting 1 6 Months 310 Adeeba Kamarulzaman, MBBS, Chee Loon Leong, MBBS, Reena Rajasuriar, PhD, Sharifah Faridah Syed Omar, MBBS, Suresh Kumar Chidambaram, MBBS, Tiang Koi Ng, MBBS 2020-04-16
GRAVID: Lung Cancer Patients COVID-19 Disease Coronavirus disease 19 infection, Lung tumor Spanish Lung Cancer Group Spain 2020-05-15 2022-05-15 GECP 20/02_GRAVID, GRAVID, NCT04344002 Phase Not Applicable Not yet recruiting 2 24 Months 200 Cristina MD Avendaño Solá, MD, Eva Pereira, Mariano MD Provencio, MD, María MD González-Cao, MD 2020-04-16
COVID-19: Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , indomethacin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Perseverance Research Center, LLC QuantRx Biomedical Corp US, Canada 2020-04-16 2020-09-30 COVID-19, HIZ-PRC-COVID-19, NCT04344457 Phase 2 Clinical Recruiting 1 5 Months 80 Brandon McCravey, Laura Chrisitans, Nicole C Hank, PhD,MCR,MHSM, Nicole C. Hank, PhD, MCR, MHSM, Teresa Gaither, NP 2020-04-17
A comprehensive trial to assess the accuracy of saliva test collected using DNA 1000 Saliva Collection Kit compared to swab test in the diagnosis of COVID-19 infection Coronavirus disease 19 infection DNA 1000 Saliva Collection Kit alone, Saliva test alone Accurate Diagnostic Labs, RUCDR Infinite Biologics Phase Not Applicable Status not specified 0 2020-04-15
Convalescent Plasma versus Standard Plasma for COVID-19 Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Stony Brook University Hospital Chembio Diagnostic Systems Inc US 2020-04-08 2021-08-31 NCT04344535, SBU-COVID19-CONVALESCENTPLASMA Phase 1/Phase 2 Clinical Recruiting 0 16 Months 500 Elliott Bennett-Guerrero, MD 2020-04-16
A Randomized, Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Coronavirus disease 19 infection, Respiratory distress syndrome clazakizumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) NYU Langone Health US 2020-03-31 2020-07-01 NCT04343989, S20-00392 Phase 2 Clinical Recruiting 0 3 Months 30 Bonnie Lonze, MD, Elaina Weldon, ACNP-BC 2020-04-16
CORTI-Covid: Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia prednisone alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon France 2020-04-30 2020-11-30 2020-001553-48, 69HCL20_0321, CORTI-Covid, NCT04344288 Phase 2 Clinical Not yet recruiting 2 7 Months 304 Marie GROUSSAUD, Marielle BUISSON, Vincent COTTIN, Vincent COTTIN, Pr 2020-04-16
CCAP-RCT: Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia Plaquenil alone, baricitinib alone, convalescent anti-SARS-CoV-2 plasma alone, sarilumab alone, standard care alone IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HS Hvidovre Hospital Denmark 2020-04-20 2021-06-15 2020-001367-88, 25032020, CCAP-RCT, NCT04345289 Phase 3 Clinical Recruiting 12 13 Months 1500 Birgitte Lindegaard Madsen, MD, PhD, Clara Clausen, MD, Isik Johansen, MD, DMSc, Jan Gerstoft, MD, DMSc, Janne Jensen, MD, PhD, Karen Brorup Heje Pedersen, MD, Kasper Iversen, MD, DMSc, Lars Østergaard, MD, DMSc, Lothar Wiese, MD, PhD, Louise Thorlacius-Ussing, MD, Michaela Tinggaard, MD, Nichlas Hovmand, MD, Ole Hilberg, MD, DMSc, Rajesh Mohey, MD, PhD, Sandra Hansen, MD, Simone Bastrup Israelsen, MD, Stine Johnsen, MD, PhD, Thomas Benfield, Thomas Benfield, MD, DMSc 2020-04-17
The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz Coronavirus disease 19 infection, Respiratory failure Routine treatment alone, Tocilizumab alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tabriz University of Medical Sciences Iran 2020-04-21 IR.TBZMED.REC.1399.010, IRCT20200406046968N1 Phase 2/Phase 3 Clinical Not yet recruiting 1 10 Adibkiya khosro, Mikaili, Haleh, Mikaili, haleh 2020-04-16
PREP-COVID: Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-14 2020-08-31 2020-001273-73, APHP200386, NCT04344379, PREP-COVID Phase 3 Clinical Not yet recruiting 6 4 Months 900 Guillaume Masson, MsC, Jean Marc Treluyer, MD PhD, Joe Elie Salem, MD, Lamiae Grimaldi, MD PhD, Michaela Semeraro, MD PhD, Olivier HANON, MD PhD, Olivier Sanchez, MD PhD, Tabassome Simon, MD PhD 2020-04-16
Study on SARS-CoV-2-Serology (COVID-19) in Bremen's public sector Coronavirus disease 19 infection Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Performa Nord Zentrum für Gesunde Arbeit Arbeitsmedizinischer Dienst Germany 2020-03-31 713, DRKS00021289 Phase Not Applicable Recruiting 1 100 Mr Dr Jan Neumann 2020-04-16
Effect of Bromhexine Hydrochloride on patients with COVID-19 Coronavirus disease 19 infection, Viral pneumonia Bromhexine Hydrochloride alone, standard regimen therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-18 IR.TBZMED.REC.1399.013, IRCT20200317046797N4 Phase 3 Clinical Not yet recruiting 1 60 Dr Khalil Ansarin, Mohammadreza Ardalan, Sepideh Zununi Vahed 2020-04-16
CCF: COVID-19 in Cardiology Unit in France: Risk Factors for Mortality Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Société Française de Cardiologie INSERM France 2020-04-10 2020-07-09 2020-02, CCF, NCT04344327 Phase Not Applicable Recruiting 10 3 Months 500 Alexandre GAUTIER, MD, Antonin TRIMAILLE, MD, Arthur DARMON, MD, Clémence DOCQ, Clément KARSENTY, MD, Corentin CHAUMONT, MD, Guillaume BONNET, MD, Joffrey CELLIER, MD, Orianne WEIZMAN, MD, Sophie RIBEYROLLES, MD, Tessa BERGOT, Vassili PANAGIDES, MD 2020-04-16
A clinical study to evaluate the safety and efficacy of Virazole in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection ribavirin (inhalation solution, respiratory syncytial virus infection), Bausch Health alone Inosine monophosphate dehydrogenase inhibitor Bausch Health Companies Inc US Phase Not Applicable Planned 0 2020-04-15
A clinical study to diagnose COVID-19 using Fiberflex Rayon (a 3D printed nasopharyngeal [NP] swab) Coronavirus disease 19 infection Fiberflex Rayon alone Markforged Neurophotometrics, Rady Children's Hospital, San Diego, Scripps Research Institute, University of California San Diego Phase Not Applicable Status not specified 0 50 2020-04-15
An open-label, interventional study to evaluate the safety and efficacy of Virazole in hospitalized adult patients with respiratory distress who tested positive for COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome ribavirin (inhalation solution, respiratory syncytial virus infection), Bausch Health alone, standard of care therapy alone Inosine monophosphate dehydrogenase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bausch Health Companies Inc Canada 238007, BHC-RIB 5401-HC Phase Not Applicable Not yet recruiting 1 2020-04-15
A Global, Randomized Clinical Trial of Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19 Coronavirus disease 19 infection selinexor alone Exportin 1 inhibitor Karyopharm Therapeutics Inc Phase Not Applicable Planned 0 2020-04-15
CORSA: Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent Coronavirus disease 19 infection next generation Sequencing (NGS) analysis alone, rapid molecular test alone, serological test alone, serum chemistry analysis alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL Azienda Unita Sanitaria Locale Della Romagna Italy 2020-03-27 2022-03-31 CORSA, IRSTB113, NCT04345315 Phase Not Applicable Recruiting 2 24 Months 500 Giovanni Martinelli, Prof, Giovanni Martinelli, Prof., Oriana Nanni, Dr 2020-04-16
Non-Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID-19 Coronavirus disease 19 infection, Respiratory failure BiPAP system alone, aerosol-reducing mask alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Lawson Health Research Institute Canada 2020-04-30 2020-08-31 137654, NCT04344925 Phase Not Applicable Not yet recruiting 1 4 Months 50 Chelsea Darling, Tarek Loubani, Tarek Loubani, MD 2020-04-16
Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey Coronavirus disease 19 infection surgery questionnaire alone Healthy volunteers accepted University of Rome Tor Vergata Italy 2020-04-02 2020-04-15 NCT04344197, S-COVID SURVEY Phase Not Applicable Recruiting 1 1200 Vittoria Bellato 2020-04-16
OAHU-COVID19: A Randomized, Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Queens Medical Centre US 2020-03-26 2021-12-31 NCT04345692, OAHU-COVID19, RA-2020-018 Phase 3 Clinical Recruiting 0 21 Months 350 May Vawer, RN, Todd Seto, MD 2020-04-16
Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic Coronavirus disease 19 infection, Inflammatory bowel disease infliximab alone, vedolizumab alone Integrin alpha-4/beta-7 antagonist, MAdCAM inhibitor, TNF alpha ligand inhibitor, TNF binding agent Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CHU De Nantes France 2020-04-15 2021-09-01 NCT04344249, RC20_0150 Phase Not Applicable Not yet recruiting 1 16 Months 850 Arnaud Bourreille, Pr 2020-04-16
Testing for COVID-19 Infection in Asymptomatic Persons Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Deutsches Krebsforschungszentrum Germany 2020-04-20 2020-12-31 COVID-19-1.0-DKFZ, NCT04345510 Phase Not Applicable Not yet recruiting 1 8 Months 500 2020-04-16
Pegylated Interferon Lambda Treatment for COVID-19 Coronavirus disease 19 infection peginterferon lambda-1a, Eiger BioPharmaceuticals alone Interferon receptor modulator, Interleukin-29 ligand Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital Eiger BioPharmaceuticals Inc US 2020-05-01 2021-12-31 2020P00XXXX, NCT04343976 Phase 2 Clinical Not yet recruiting 0 20 Months 40 Arthur Kim, MD, Jenna Gustafson, MSc, Raymond Chung, MD 2020-04-16
Treatment of COVID-19 with allogeneic mesenchymal cells (MSV) Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia allogeneic mesenchymal stem cells MSV-allo alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Citospin Sociedad Limitada Spain 2020-001682-36, MSV_COVID Phase 1/Phase 2 Clinical Recruiting 1 24 CRO, Effice spi S.L. 2020-04-16
Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection Coronavirus disease 19 infection, Respiratory distress syndrome sevoflurane alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Incliva Spain 2020-04-14 2020-001379-34, SEVO-COVID19 Phase 4 Clinical Recruiting 1 50 Subdirectora Científica 2020-04-16
Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine Coronavirus disease 19 infection Dolquine (Products and technology SL) alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Barcelona Institute for Global Health Spain 2020-04-08 02/04/2020-001, 2020-001587-29 Phase 4 Clinical Recruiting 1 714 Clara Menéndez 2020-04-16
COVID-19 HUF: Clinical Trial to Evaluate Efficacy of Three Types of Treatment in Patients With Pneumonia by COVID-19 Coronavirus disease 19 infection, Viral pneumonia Variable regimens including Dolquine (Products and Technology SL) , baricitinib , imatinib , lopinavir + ritonavir Abl tyrosine kinase inhibitor, Bcr protein inhibitor, HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Universitario de Fuenlabrada Centro Nacional de Investigaciones Oncologicas Spain 2020-04-13 2020-09-30 2020-001321-31, 24032020, COVID-19 HUF, NCT04346147 Phase 2 Clinical No longer recruiting 2 5 Months 165 Comisión de Investigación, David Bernal, Ph MD 2020-04-17
Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) US Department of Defense US 2020-04-30 2020-08-31 NCT04343677, PENTAGON 20-1 Phase 2 Clinical Not yet recruiting 0 4 Months 1450 Angela Phillips, PhD, David S Robinson, MD, John S Baxter, MD, JD, Scott A Wallace, MD 2020-04-16
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild-to-Moderate COVID-19 Coronavirus disease 19 infection, Viral pneumonia leronlimab alone CCR5 chemokine antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) CytoDyn Inc US 2020-04-01 2021-04-04 CD10_COVID-19, NCT04343651 Phase 2 Clinical Recruiting 0 12 Months 75 Kush Dhody, MBBS, MS, CCRA 2020-04-16
COVIDAtoZ: Coronavirus 2019 - Using Ascorbic Acid and Zinc Supplementation Coronavirus disease 19 infection ascorbic acid alone, zinc gluconate alone, ascorbic acid plus zinc gluconate Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Cleveland Clinic Foundation US 2020-04-08 2021-04-30 COVIDAtoZ, IRB 20-361, NCT04342728 Phase Not Applicable Recruiting 0 12 Months 520 Milind Desai, M. D. 2020-04-17
CloroCOVID19II: Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection Coronavirus disease 19 infection chloroquine diphosphate alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Foundation of Tropical Medicine Doctor Heitor Vieira Dourado Brazil 2020-04-08 2020-09-30 CAAE: 30504220.5.0000.0005, CloroCOVID19II, NCT04342650 Phase 2b Clinical Recruiting 1 5 Months 210 Fernando Val, PhD, Marcus Lacerda, MD, Mayla Borba, MD 2020-04-15
Convalescent Plasma in the Treatment of COVID-19 Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Saint Francis Care US 2020-04-10 2021-04-01 NCT04343261, SFH-20-23 Phase 2 Clinical Not yet recruiting 0 11 Months 15 Latha Dulipsingh, MD 2020-04-15
The Role of Resistant Potato Starch in COVID-19 Infection Coronavirus disease 19 infection Bob's red mill resistant potato starch alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Yale University University of Michigan, University of Minnesota US 2020-05-01 2021-05-01 2000027887, NCT04342689 Phase Not Applicable Not yet recruiting 0 12 Months 1300 Mary M Riwes, DO, Sherry Mansour, MD, MS 2020-04-17
Clinical trial to assess the efficacy and safety of cyclosporine A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection Coronavirus disease 19 infection Variable regimens including chloroquine , ciclosporin, Novartis , darunavir , interferon beta-1b , lopinavir , ritonavir , spironolactone , tocilizumab Aldosterone antagonist, Calcineurin inhibitor, Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz Jimenez Diaz Foundation Spain 2020-04-09 2020-001262-11, FJD-COVID19-20-01 Phase 4 Clinical Recruiting 1 120 CLINICAL RESEARCH UNIT 2020-04-15
Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19 Coronavirus disease 19 infection melatonin (controlled release, insomnia), Neurim alone Melatonin receptor agonist Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Spain 2020-04-09 2020-001530-35, MeCOVID Phase 4 Clinical Recruiting 1 450 Alberto Borobia 2020-04-14
DIC: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Clinical Trial Coronavirus disease 19 infection Variable regimens including Interferon beta-1A , Interferon beta-1B , hydroxychloroquine , lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-10 2020-04-24 DIC, DIFFERENT INTERFERONS IN COVID, NCT04343768 Phase 4 Clinical Recruiting 2 60 Ilad Alavi Darazam, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD 2020-04-17
COVID-19 Endo: COVID-19 Endoscopy Survey Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Al-Azhar University Iran, Egypt, US 2020-04-10 2020-12-10 COVID-19 Endo, NCT04342637, WES-2 Phase Not Applicable Not yet recruiting 3 8 Months 40 Mohamed Alboraie, Mohamed Alboraie, MD, MRCP(UK) 2020-04-14
SARICOVID: Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild to moderate pneumonia and COVID19 infection versus standard of care Coronavirus disease 19 infection, Viral pneumonia Variable regimens including azithromycin , hydroxychloroquine , sarilumab IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital del Mar Instituto de Salud Carlos III Spain 2020-04-11 2020-001290-74, SARICOVID, SARICOVID Phase 3 Clinical Recruiting 1 216 Ana Aldea 2020-04-15
Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19 Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University Patient Centered Outcome Research Institute US 2020-04-10 2099-12-31 NCT04342806, PRO00105284 Phase Not Applicable Recruiting 0 956 Months 100000 Emily O'Brien, PhD, Laura Webb, Nina Y Hines 2020-04-16
Clinical trial of Dalargin hexapeptide for the treatment of coronavirus pneumonias complicated by difficulty breathing Coronavirus disease 19 infection, Viral pneumonia dalargin hexapeptide alone Federal Medical Biological Agency Phase Not Applicable Recruiting 0 2020-04-14
MetCOVID: Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 Coronavirus disease 19 infection methylprednisolone sodium succinate alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Foundation of Tropical Medicine Doctor Heitor Vieira Dourado Brazil 2020-04-30 2020-09-30 CAEE: 30615920.2.0000.0005, MetCOVID, NCT04343729 Phase 2b Clinical Not yet recruiting 1 5 Months 420 Fernando Val, Marcus Lacerda 2020-04-17
Early tracheostomy in COVID-19 Coronavirus disease 19 infection Airway management alone, COVID-19 medications alone, Mechanical ventilation alone, Tracheotomy tube alone Baqiyatallah University of Medical Sciences Iran 2020-04-06 2020-04-13 IR.BMSU.REC.1399.055, IRCT20180129038542N1 Phase Not Applicable Completed 1 30 Hossein Pirmohammadi, Shahriar Najafizadeh 2020-04-15
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia mesenchymal stem cell therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Iranian Academic Center For Education Culture & Research, National Institute for Medical Research Developement Iran 2020-03-15 2020-04-25 IR.NIMAD.REC.1398.412, IRCT20200217046526N1 Phase 1/Phase 2 Clinical No longer recruiting 2 1 Month 6 Abdol Hossein Shahverdi, Hossein Baharvand, Masoume Nouri, Mohammad Reza Hashemian, Morteza Zarrabi, Rasoul Alian Nejad 2020-04-17
Investigation of the effect of Zufa syrup on clinical symptoms with suspected Corona (COVID-19) Coronavirus disease 19 infection Zufa syrup (Booali Daroo Pharmaceutical Company) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Deputy of Research and Technology, Qom University of Medical Sciences BooaliDaroo pharmaceutical company Iran 2020-03-10 IR.MUQ.REC.1398.165, IRCT20200404046934N1 Phase 3 Clinical Recruiting 1 130 Ehsan Sharifi pour, Majid Asghari, Razieh Borujerdi 2020-04-15
Effect of crocetin on COVID-19 Coronavirus disease 19 infection crocetin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.052, IRCT20081019001369N3 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi 2020-04-15
Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm Coronavirus disease 19 infection, Viral pneumonia Variable regimens including hydroxychloroquine , intravenous immunoglobulin (IVIG) (Behring company) , lopinavir + ritonavir , ribavirin HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tabriz University of Medical Sciences Iran 2020-04-20 2020-07-22 IR.TBZMED.REC.1399.003, IRCT20200317046797N3 Phase 3 Clinical Not yet recruiting 1 3 Months 100 Dr Khalil Ansarin, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed 2020-04-17
BCG-CORONA-ELDERLY: Reducing hospital admission of elderly in Coronavirus pandemic by boosting the immune system through vaccination with bacillus Calmette-Guerin (BCG) Coronavirus disease 19 infection BCG vaccine alone Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Radboudumc Netherlands 2020-04-09 2020-001591-15, BCG-CORONA-ELDERLY, NL73430.091.20 Phase 4 Clinical Recruiting 1 1600 Jaap ten Oever 2020-04-15
Comparative effectiveness of Chloroquine and Vitamin C prophylaxis in household contacts of confirmed COVID-19 patients Coronavirus disease 19 infection chloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Health System Research Institute (HSRI), Siriraj Hospital Thailand 2020-04-27 TCTR20200404004 Phase 4 Clinical Not yet recruiting 1 400 Suvimol Niyomnaitham 2020-04-15
Use of Covid-19 Rapid Test for Hospital Care: GI Procedure Coronavirus disease 19 infection Covid-19 rapid test alone, endoscopy alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Chulalongkorn University Thailand 2020-03-19 TCTR20200405001 Phase Not Applicable Recruiting 1 20 Sombat Treeprasertsuk, Tongluk Teerasarntipan 2020-04-15
COVID19PUGG2: National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19 Coronavirus disease 19 infection Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-03-22 2020-04-05 AR20-0031V1, COVID19PUGG2, NCT04343781 Phase Not Applicable Completed 1 353 Cédric Annweiler, M.D., Ph.D. 2020-04-15
Pragmatic clinical trial of hydroxychloroquine in the treatment of oncohematological patients and health professionals with COVID-19 infection without radiological alteration Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Catalan de Oncologia Spain 2020-04-01 2020-001765-37, PROTOCOLO/ICO/COVID20 Phase 2 Clinical Recruiting 1 103 Margarita García Martín 2020-04-15
Randomized, open, pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection Coronavirus disease 19 infection sarilumab alone IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Universitario de La Princesa Sanofi SA Spain 2020-04-09 2020-001634-36, SARCOVID Phase 2 Clinical Recruiting 1 30 Rosario García de Vicuña 2020-04-15
A Study of LY-3127804 in Participants With COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia LY-3127804 alone, Standard of care treatment alone Angiopoietin ligand-2 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Eli Lilly & Co National Institute of Allergy and Infectious Diseases US 2020-04-18 2020-07-10 17824, I7W-MC-UDAA, NCT04342897 Phase 2 Clinical Not yet recruiting 0 2 Months 200 2020-04-16
Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID-19 Coronavirus disease 19 infection chlorine dioxide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Genesis Foundation, United States Colombia 2020-04-01 2020-06-01 GENESIS AKCOVID- FG-1, NCT04343742 Phase Not Applicable Recruiting 1 2 Months 20 BLANCA BOLANO, researcherer, EDUARDO INSIGNARES-CARRIONE, Research Direc., Eduardo Insignares Carrione, YOHANNY ANDRADE, INVESTIGATOR, oswaldo leyva, researcher, yohanny andrade, researcher 2020-04-15
A Study on the Prospective, Cohort Library of COVID-19 in Southern Coronavirus disease 19 infection, Viral pneumonia The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University Cangnan People's Hospital, Lishui People's Hospital, People's Hospital of Pingyang, Ruian People's Hospital, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou Medical University, Wenzhou Yueqing People's Hospital, Yongjia People's Hospital China 2020-03-16 2021-03-31 NCT04342702, SAHOWMU-CR2020-NCP-202 Phase Not Applicable No longer recruiting 2 12 Months 504 Xiaokun Li 2020-04-15
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia mesenchymal stem cells alone, extracellular vessicles plus mesenchymal stem cells Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Iranian Academic Center For Education Culture & Research, National Institute for Medical Research Developement Iran 2020-04-05 IR.NIMAD.REC.1398.412, IRCT20200217046526N2 Phase 2/Phase 3 Clinical Recruiting 2 60 Abdol Hossein Shahverdi, Hossein Baharvand, Masoume Nouri, Mohammad Reza Hashemian, Morteza Zarrabi, Rasoul Alian Nejad, Reza Mlekzadeh 2020-04-15
CRASH-19: Coronavirus Response - Active Support for Hospitalized Covid-19 Patients Coronavirus disease 19 infection aspirin alone, losartan alone, simvastatin alone, Variable regimens including aspirin , losartan , simvastatin Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, HMG CoA reductase inhibitor Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) London School of Hygiene and Tropical Medicine Pakistan, Nigeria 2020-04-30 2021-08-31 2020-KEP-420, CRASH-19, NCT04343001 Phase 3 Clinical Not yet recruiting 2 16 Months 10000 Aasia Kayani, Haleema Shakur-Still, Ian Roberts, Kiran Javaid, Nike Bello, Oladapo Olayemi, Rizwana Chaudhri, Temitayo Shokunbi 2020-04-15
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) Coronavirus disease 19 infection, Viral respiratory tract infection nitazoxanide (controlled-release, viral infections), Romark alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) Romark Laboratories LC 2020-04-30 2020-08-31 NCT04343248, RM08-3006 Phase 3 Clinical Not yet recruiting 0 4 Months 600 Matthew Bardin, PharmD, BCPS 2020-04-17
STOP-COVID: Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Brigham & Women's Hospital US 2020-04-01 2022-06-01 2007P000003, NCT04343898, STOP-COVID Phase Not Applicable Recruiting 0 26 Months 2000 David E Leaf, MD, MMSc, Shruti Gupta, MD, MPH 2020-04-17
EPILOGUE: Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment Coronavirus disease 19 infection, Drug dependence psychoactive substances consumption alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier France 2020-04-08 2020-09-30 EPILOGUE, NCT04343339, RECHMPL20_0195 Phase Not Applicable Recruiting 1 5 Months 100 Hélène Donnadieu-Rigole, MD PhD, hélène Donnadieu-Rigole, doctor 2020-04-16
COVID-19 Community Research Partnership Coronavirus disease 19 infection IgM/IgG test alone Healthy volunteers accepted Wake Forest University Health Sciences, US US 2020-04-30 2021-12-31 IRB00064912, NCT04342884 Phase Not Applicable Not yet recruiting 0 20 Months 150000 John W Sanders, MD, MPH&TM, Wake Forest Baptist Medical Center 2020-04-16
STOP COVID: A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection Coronavirus disease 19 infection fluvoxamine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Washington University in St Louis US 2020-04-10 2020-07-01 202004023, NCT04342663, STOP COVID Phase 2 Clinical Recruiting 0 2 Months 152 Angela Stevens, Eric J Lenze, MD, Marissa Rhea, MA 2020-04-16
A clinical study to assess leronlimab in the treatment of patients with severe COVID-19 Coronavirus disease 19 infection leronlimab alone CCR5 chemokine antagonist CytoDyn Inc US Phase Not Applicable Status not specified 0 2020-04-14
FASTER: Facilitating A SARS CoV-2 Test for Rapid triage Coronavirus disease 19 infection, SARS coronavirus infection, Streptococcus pneumoniae infection Liverpool School of Tropical Medicine, Pfizer Inc FASTER Phase Not Applicable Recruiting 0 400 2020-04-14
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection Coronavirus disease 19 infection convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hackensack Meridian Health US 2020-04-09 2021-04-30 NCT04343755, PRO2020-0375 Phase 2a Clinical Recruiting 0 12 Months 55 Mariefel Vendivil, Marlo Kemp, Michele L Donato, MD 2020-04-18
SAFER: SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response Coronavirus disease 19 infection, SARS coronavirus infection, Streptococcus pneumoniae infection Liverpool School of Tropical Medicine, Pfizer Inc SAFER Phase Not Applicable Recruiting 0 100 2020-04-14
New: Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia Coronavirus disease 19 infection Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Dr Cipto Mangunkusumo General Hospital Indonesia 2020-04-12 2020-12-31 MH-COVID19, NCT04343664, New Phase Not Applicable Not yet recruiting 1 8 Months 10000 Belinda J Murtani, dr., Tjhin Wiguna, PhD 2020-04-15
Ruxo-Sim-20: Study of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19 Coronavirus disease 19 infection ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis plus simvastatin HMG CoA reductase inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HM Research Foundation Hospitals Apices Soluciones, S.L. Spain 2020-04-12 2020-05-13 2020-001405-23, NCT04348695, Ruxo-Sim-20, Ruxo-Sim-20 Phase 2 Clinical Recruiting 2 1 Month 94 FUNDACION DE INVESTIGACION HM HOSPI, Jesús García Donas, MD, Paula Villares Fernández, MD 2020-04-18
Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome HA330 hemoperfusion alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) King Chulalongkorn Memorial Hospital ASTROMED CO., LTD Thailand 2020-05-01 TCTR20200409006 Phase Not Applicable Not yet recruiting 1 206 Nattachai Srisawat 2020-04-15
Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19 Coronavirus disease 19 infection Biovitals alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Hong Kong Hong Kong 2020-04-01 2022-01-31 COVID19_BIOVITALS_PROTOCOL_1, NCT04343794 Phase Not Applicable Recruiting 2 22 Months 200 David Siu, MD, David Siu, MD FRCP, Ivan FN Hung MD, Ivan Hung, MD, Ivan Hung, MD FRCPath 2020-04-16
ECMO-COVID-19: Place of Venovenous ECMO in the Management of Refractory ARDS Associated with SARS-COV-2 Coronavirus disease 19 infection, Respiratory distress syndrome Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hopitaux Universitaires de Strasbourg France 2020-04-01 2020-04-15 7772, ECMO-COVID-19, NCT04343404 Phase Not Applicable Recruiting 1 100 Anne OLLAND, MD, PhD, Ferhat MEZIANI, MD, PhD, Francis SCHNEIDER, MD, PhD, Jean-Philipe MAZZUCOTELLI, MD, PhD, Julien POTTECHER, MD, PhD, Michel MERTES, MD, PhD, Pierre-Emmanuel FALCOZ, MD, PhD, Saïd CHAYER, PhD, HDR 2020-04-15
Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Heart injury, Viral pneumonia Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jiangsu Provincial People’s Hospital China 2020-01-01 2020-04-15 ChiCTR2000031752 Phase Not Applicable No longer recruiting 2 3 Months 75 Gang Yang, Yun Liu 2020-04-15
CORIMUNO-NIVO: Trial Evaluating Efficacy and Safety of Nivolumab (Optivo) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Coronavirus disease 19 infection nivolumab alone Programmed cell death protein 1 inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-15 2020-09-30 APHP200389-5, CORIMUNO-NIVO, NCT04343144 Phase 2 Clinical Not yet recruiting 1 5 Months 92 Jacques Cadranel, MD PhD 2020-04-15
Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 Infection Coronavirus disease 19 infection hyperbaric oxygen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ochsner Health System US 2020-04-30 2020-06-30 NCT04343183, STUDY00001051 Phase 2 Clinical Not yet recruiting 0 2 Months 48 Jeffery S Kuo, MD, John Engle, John F Engle, MD, Michael D Lindley, MD 2020-04-15
Urgent Public Health Research Study: A phase IIa clinical trial of ORBCEL for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS) Coronavirus disease 19 infection, Respiratory distress syndrome ORBCEL-C alone Orbsen Therapeutics Ltd Wellcome Trust UK Urgent Public Health Research Study Phase 2a Clinical Recruiting 1 Belfast Health and Social Care Trust, Queen's University Belfast 2020-04-14
Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai Coronavirus disease 19 infection, Viral pneumonia Nursing care alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shanghai Sixth People’s Hospital Shanghai Jiao Tong University China 2020-01-22 2020-02-29 2020RK44, ChiCTR2000031770 Phase Not Applicable No longer recruiting 1 1 Month 119 Sanlian Hu, Yuli Hu 2020-04-15
A Phase IIa/IIb study of FW-1022 for the potential treatment of COVID-19 Coronavirus disease 19 infection FW-1022 alone First Wave Bio, Inc EU, US 2020-06-30 Phase 2 Clinical Planned 0 2020-04-15
Evaluating the effect of Phyllanthus emblica on COVID 19 patients Coronavirus disease 19 infection Phyllanthus emblica drink intake alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ahvaz University of Medical Sciences Iran 2020-04-13 IR.AJUMS.REC.1399.011, IRCT20200404046937N2 Phase 3 Clinical Recruiting 3 60 Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani 2020-04-15
A clinical study to assess LUNAR-COV19 in healthy subjects for the treatment of COVID-19 infectiion Coronavirus disease 19 infection LUNAR-COV19 alone Healthy volunteers accepted Arcturus Therapeutics Inc Singapore Phase Not Applicable Planned 1 76 2020-04-14
Ivermectin Adjuvant to Hydroxychloroquine in COVID19 Patients Coronavirus disease 19 infection, Viral pneumonia hydroxychloroquine plus ivermectin Chloride channel modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Baghdad Iraq 2020-04-08 2020-08-01 NCT04343092, PRO20040001 Phase 1 Clinical Not yet recruiting 1 3 Months 50 2020-04-15
A phase II, double-blind, randomized, placebo-controlled study to evaluate safety and efficacy of intranasal vazegepant for the treatment of COVID-19 infection associated pulmonary complications Coronavirus disease 19 infection, Lung disease vazegepant alone CGRP receptor antagonist Biohaven Pharmaceutical Holding Co Ltd Thomas Jefferson University US Phase 2 Clinical Not yet recruiting 0 Jesse Roman, Michael Baram, Steven Schnittman 2020-04-14
A first-in-human clinical trial of peptide-based vaccine for the potential treatment of COVID-19 Coronavirus disease 19 infection peptide-based vaccine (COVID-19), Axon Neuroscience alone Coronavirus spike glycoprotein inhibitor Axon Neuroscience SE 2020-09-30 Phase Not Applicable Planned 0 2020-04-15
Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs Coronavirus disease 19 infection, Viral pneumonia ciclosporin, Novartis plus tocilizumab (intravenous), Roche/Chugai Calcineurin inhibitor, IL-6 receptor antagonist, IL-6 receptor modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Vall D'Hebron Spain 2020-04-09 2020-001437-12, COVID-19_ASS Phase 4 Clinical Recruiting 1 290 Salvador Augustin 2020-04-15
A nested phase II, two-part study to evaluate TD-0903 in hospitalized patients with COVID-19 Coronavirus disease 19 infection TD-0903 alone JAK tyrosine kinase inhibitor Theravance Biopharma Inc US, UK, Europe Phase 2 Clinical Planned 1 2020-04-15
A first in human, phase I study to evaluate safety of single- and multiple-ascending doses of TD-0903 in healthy subjects Acute lung injury, Coronavirus disease 19 infection TD-0903 alone JAK tyrosine kinase inhibitor Healthy volunteers accepted Theravance Biopharma Inc UK 2020-04-30 Phase 1 Clinical Planned 1 2020-04-15
A clinical study of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in Lupus patients Coronavirus disease 19 infection Lupus therapy alone, hydroxychloroquine alone Lupus Therapeutics US, Canada Phase Not Applicable Planned 1 20000 2020-04-16
SOS-COVID19: Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome Coronavirus disease 19 infection, Respiratory failure Auricular neuromodulation alone, SEDATELEC alone, chlorhexidine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fondation Ophtalmologique Adolf De Rothschild France 2020-04-30 2020-06-30 CRN_2020_8, NCT04341415, SOS-COVID19 Phase Not Applicable Not yet recruiting 1 2 Months 60 Amélie YAVCHITZ, Claire-Marie RANGON 2020-04-16
ECMO-VID: Early Versus Late ECMO Therapy in COVID-19 Induced ARDS Coronavirus disease 19 infection, Respiratory distress syndrome Extracorporal Membrane Oxygenation (ECMO) Implantation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Klinikum der Albert-Ludwigs Universitaet Freiburg, Rheinisch-Westfaelische Technische Hochschule Aachen, University Hospital Muenster Germany 2020-06-01 2025-12-01 ECMO-VID, ECMO-VID, NCT04341285 Phase Not Applicable Not yet recruiting 1 66 Months 200 Peter Rosenberger, Prof. 2020-04-17
Predicting Factors for Progression to Severe Illness of COVID-19 Infection Coronavirus disease 19 infection Hospital Raja Permaisuri Bainun Malaysia 2020-04-20 2020-08-31 54622, NMRR-20-704-54622 Phase Not Applicable Not yet recruiting 1 4 Months Dr Ker Hong Bee, Dr LEONG E LI 2020-04-15
MentalStatCOVID: Mental Health Status of Stable Hospitalized COVID-19 Patients in Hospital Kuala Lumpur, Hospital Sungai Buloh and Hospital Permai Johor Bahru Anxiety disorder, Coronavirus disease 19 infection, Depression National Institutes of Health Malaysia Malaysia 2020-04-15 2020-05-31 54541, MentalStatCOVID, NMRR-20-711-54541 Phase Not Applicable Recruiting 3 1 Month Dr Mohd Shaiful Azlan Bin Kassim, Dr Muhammad Najib bin Abdullah, Dr Norazam Bin Harun, Dr Umi Adzlin binti Silim 2020-04-15
QT interval with HCQ in COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Taiping Hospital Malaysia 2020-04-13 2020-04-30 54651, NMRR-20-712-54651 Phase Not Applicable Status not specified 1 Dr Cheah Wee Kooi, Dr Narwani Hussin 2020-04-15
COVID in Malaysia Coronavirus disease 19 infection National Institutes of Health Malaysia Malaysia 2020-04-11 2020-12-31 54598, NMRR-20-720-54598 Phase Not Applicable Recruiting 3 8 Months Dr Chong Zhuo Lin 2020-04-16
CXR IN COVID-19 Coronavirus disease 19 infection, Viral pneumonia chest radigraph alone Hospital Sungai Buloh Malaysia 2020-04-05 2020-12-31 54589, NMRR-20-726-54589 Phase Not Applicable Not yet recruiting 1 8 Months DR AIDA BINTI ABDUL AZIZ, Dr Mohan Dass Pathmanathan 2020-04-15
Evaluation of IL-6 cytokine levels during progression of severe COVID-19 disease in relation to assessing the efficacy of intravenous tocilizumab treatment Coronavirus disease 19 infection tocilizumab (intravenous), Roche/Chugai alone IL-6 receptor antagonist, IL-6 receptor modulator Universiti Malaysia Sabah Malaysia 2020-04-14 2021-02-27 54610, NMRR-20-729-54610 Phase Not Applicable Status not specified 2 10 Months Dr Fong Siew Moy, Dr Lee Heng Gee, Dr Shahleni A/P Paramasivam, Nadirah binti Sulaiman 2020-04-15
Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sociedad Española de Farmacia Hospitalaria Instituto de Salud Carlos III Spain 2020-04-06 2020-001421-31, QUINAVID-19 Phase 4 Clinical Recruiting 1 1530 Emilio Garcia Cabrera 2020-04-15
Interferon beta 1b in COVID-19 Coronavirus disease 19 infection Variable regimens including hydroxychloroquine , interferon beta 1 b , lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mazandaran University of Medical Sciences Iran 2020-03-25 IR.MAZUMS.REC.1399.005, IRCT20190804044429N1 Phase 2/Phase 3 Clinical Recruiting 1 70 Majid Saeedi, Monireh Ghazaeian 2020-04-14
Evaluation the effect of licorice for treatment of coronavirus Coronavirus disease 19 infection licorice extract alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.047, IRCT20200404046933N1 Phase 2 Clinical Not yet recruiting 1 40 Dr. Dehghan Nayeri, Gholamreza Karimi, Mohsen Tafaghodi 2020-04-15
PROSCLOROCOV 19: Post-exposure hydroxycloroquine prophylaxis for Covid 19 Coronavirus disease 19 infection hydroxycloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabriz University of Medical Sciences Iran 2020-04-20 IR.TBZMED.REC.1399.012, IRCT20130306012728N8, PROSCLOROCOV 19 Phase 3 Clinical Not yet recruiting 1 500 Behrouz Naghili, Sakineh Hajebrahimi 2020-04-15
Evaluation and comparison of the effectiveness of standard treatment with standard treatment plus Vitamin A in treatment in covid19 patients Coronavirus disease 19 infection standard national treatment alone, vitamin A alone Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Saveh University of Medical Sciences Iran 2020-04-07 IR.SAVEHUMS.REC.1399.003, IRCT20180520039738N2 Phase 3 Clinical No longer recruiting 2 140 Dr, Mohammad Ghorbanli, Dr., Hamidreza Koohestani, Hasan Mozaffar, Mahmood Karimy, Mohamadreza Rohani, Mohammadreza Rouhani 2020-04-14
A clinical study of SAB-185 for the treatment in COVID-19 patients Coronavirus disease 19 infection SAB-185 alone CSL Behring (UK) North America Phase Not Applicable Planned 0 2020-04-14
Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease Coronavirus disease 19 infection Convalescent Plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Semnan University of Medical Sciences Iran 2020-04-20 IR.SEMUMS.REC.1399.004, IRCT20151228025732N53 Phase 3 Clinical Not yet recruiting 1 12 Maral Hemati, Parviz Kokhaei 2020-04-14
CRR: COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial) Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fiona Stanley Hospital, South Metropolitan Area Health Service Australia 2020-04-07 ACTRN12620000444987, ANZCTR12620000444987, CRR Phase Not Applicable Not yet recruiting 1 100000 Ms Giuliana Daulerio, Prof Toby Richards 2020-04-14
A Phase II Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc US Phase 2 Clinical Planned 0 2020-04-13
A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc Australia Phase Not Applicable Planned 1 2020-04-13
A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc South Korea Phase Not Applicable Planned 1 2020-04-13
Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care Coronavirus disease 19 infection exercises alone, telerehabilitation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Flinders Medical Centre Flinders University of South Australia Australia 2020-05-01 ACTRN12620000443998p, ANZCTR12620000443998 Phase Not Applicable Not yet recruiting 1 58 A/Prof Kate Laver, Prof Maria Crotty 2020-04-14
A Phase II Study to Assess The Effect of Ifenprodil in Patients with Severe COVID-19 Infection Coronavirus disease 19 infection repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone NMDA receptor epsilon 2 subunit inhibitor Algernon Pharmaceuticals, Nash Pharmaceuticals Inc Canada Phase 2 Clinical Planned 1 2020-04-13
GARGLES: A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients Coronavirus disease 19 infection, Viral infection hydrogen peroxide alone, povidone-iodine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Aga khan University University Of Karachi Pakistan 2020-07-01 2021-03-31 2020-SUR-ERC-20, GARGLES, NCT04341688 Phase 2 Clinical Not yet recruiting 1 9 Months 40 Farhan R Khan, MS, FCPS, Farhan Raza Khan, Syed MR Kazmi, FCPS 2020-04-17
MEFLOCOVID-19: Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19) Coronavirus disease 19 infection mefloquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universidad Miguel Hernandez de Elche Foundation for Health Research and Biomedical Valencia Spain 2020-03-30 2020-001194-69, MEFLOCOVID-19, MEFLOCOVID-19 Phase 3 Clinical Recruiting 1 200 Unidad de Enfermedades Infecciosas 2020-04-14
Clinical trials with low-dose rapamycin to protect elderly from COVID-19 Coronavirus disease 19 infection sirolimus alone mTOR inhibitor The Biogerontology Research Foundation Phase Not Applicable Planned 0 2020-04-14
COV-HCQ: Hydroxychloroquine for COVID-19 Coronavirus disease 19 infection Hydroxychloroquine Sulfate alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Bernhard-Nocht-Institute for Tropical Medicine, Robert Bosch Medical Center, Universitätsklinikum Hamburg-Eppendorf Germany 2020-03-29 2022-02-28 2020-001224-33, COV-HCQ, COV-HCQ, NCT04342221 Phase 3 Clinical Recruiting 1 23 Months 220 Benjamin Mordmüller, Prof., Diane Egger-Adam, Dr., Thirulamaisamy Velavan, Prof., Thirumalaisamy Velavan, Prof. 2020-04-13
PanCOVID19: Efficacy of different treatments in patients infected with COVID-19 Coronavirus disease 19 infection, Viral pneumonia Dolquine (Products and Technology SL) alone, azithromycin cinfa (Laboratorios Cinfa, SA) alone, lopinavir + ritonavir alone HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Servicio de Farmacología Clínica, Unidad de Ensayos Clínicos (UCICEC) Spain 2020-03-27 2020-001156-18, PanCOVID19, PanCOVID19 Phase 3 Clinical Recruiting 1 1000 Alberto Borobia 2020-04-14
Acquiring Convalescent Specimens for COVID-19 Antibodies Coronavirus disease 19 infection Blood draw alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Columbia University US 2020-03-25 2021-03-31 AAAS9517, NCT04342195 Phase Not Applicable Recruiting 0 12 Months 12 Brett Gray, David Ho, M.D,, Yang Luo, PhD 2020-04-14
Hydroxychloroquine, Hydroxychloroquine, Azithromycin in the Treatment of SARS CoV-2 Infection Coronavirus disease 19 infection chloroquine sulfate alone, hydroxychloroquine alone, Variable regimens including azithromycin , chloroquine sulfate , hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Washington University School of Medicine, US Cigna Corp US 2020-04-04 2021-08-01 202003188, NCT04341727, WU352 Phase 3 Clinical Recruiting 0 15 Months 500 Adriana Rauseo Acevedo, MD, Carlos Mejia Chew, RN, Jane O'Halloran, MD PhD, Jane O'Hallorhan, MB BA PhD, Klebert Michael, RN PhD, Michael Klebert, RN PhD, Philip Spinella, MD, Rachel M. Presti, Rachel Presti, MD PhD, Spec Andrej, MD 2020-04-16
Tocilizumab in COVID-19 Coronavirus disease 19 infection tocilizumab (AryoGen Pharmed Co.) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) AryoGen Pharmed Co Iran 2020-03-15 IR.NIMAD.REC.1398.414, IRCT20150303021315N17 Phase 3 Clinical Recruiting 9 500 Dr. Ali Javad Mousavi, Dr. Behzad Mohsenpour, Dr. Davood Attaran, Dr. Ehsan Sharifipour, Dr. Mohammad Reza Salehi, Dr. Nafiseh Abdollahi, Dr. Payam Tabarsi, Farzin Khorvash, Nassim Anjidani, Payam Tabarsi, Roya Ghasemian, Rozita Khodashahi 2020-04-15
A phase I safety clinical study of CORAVAX for the potential treatment of COVID-19 Coronavirus disease 19 infection CORAVAX alone Coronavirus spike glycoprotein inhibitor Thomas Jefferson University Phase 1 Clinical Planned 0 2020-04-15
SCOPE: Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia sirolimus alone mTOR inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Cincinnati US 2020-04-30 2020-09-30 2020-0337, NCT04341675, SCOPE Phase 2 Clinical Not yet recruiting 0 5 Months 30 Nishant Gupta, MD 2020-04-13
Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus Kaletra in hospitalized patients with COVID-19 Coronavirus disease 19 infection Hydroxychloroquine (Iran daroo Co, Iran) plus favipiravir (Nafas farmed Co, Iran) Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ardabil University of Medical Sciences Iran 2020-04-29 IR.ARUMS.REC.1399.012, IRCT20150808023559N20 Phase 1/Phase 2 Clinical Not yet recruiting 1 100 Somaieh Matin 2020-04-14
The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients Coronavirus disease 19 infection Standard of care alone, Sovodak plus ribavirin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mazandaran University of Medical Sciences Iran 2020-03-05 IR.MAZUMS.REC.1399.019, IRCT20200328046886N1 Phase 3 Clinical No longer recruiting 1 48 Hamideh Abbaspour Kasgari 2020-04-14
A short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome, serious complications associated with severe COVID-19 disease Coronavirus disease 19 infection anakinra plus emapalumab Interferon gamma ligand inhibitor, Type I IL-1 receptor antagonist Swedish Orphan Biovitrum AB Italy Phase Not Applicable Not yet recruiting 1 2020-04-14
ASC COVID-19: ASC Therapy for Patients With Severe Respiratory COVID-19 Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome, Viral pneumonia allogeneic adipose-derived mesenchymal stromal cell alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rigshospitalet, Denmark Denmark 2020-04-20 2021-04-30 2020-001330-36, ASC COVID-19, NCT04341610 Phase 1/Phase 2 Clinical Not yet recruiting 1 12 Months 40 Abbas Ali Qayuum, MD PhD, JKastrup, Jens Kastrup, Professor MD 2020-04-14
CONCOVID: Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease Coronavirus disease 19 infection, SARS coronavirus infection Convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Erasmus University Rotterdam Maasstad Hospital Netherlands 2020-04-01 2020-07-01 CONCOVID, NCT04342182, NL73489.078.20 Phase 2/Phase 3 Clinical Recruiting 2 3 Months 426 Arvind Gharbharan, MD, Bart Rijnders, MD, PhD, Casper Rokx, MD, PhD, Jan Den Hollander, MD, PhD 2020-04-15
NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure Coronavirus disease 19 infection, Respiratory failure aggravation monitoring alone, continuous positive airway pressure (CPAP) alone, non-invasive ventilation (NIV) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Morales Meseguer (Murcia, Spain) Spain 2020-04-01 2020-07-01 08-04-2020, NCT04342104 Phase Not Applicable Recruiting 1 3 Months 100 Antonio Esquinas, Miguel Filipe Martins de Matos Navarro Guia, Miguel Guia 2020-04-14
A clinical study of silmitasertib in the treatment of patients with COVID-19 infection Coronavirus disease 19 infection silmitasertib alone Casein kinase II inhibitor Senhwa Biosciences Inc National Institute of Allergy and Infectious Diseases Phase Not Applicable Planned 0 2020-04-13
Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults Coronavirus disease 19 infection, SARS coronavirus infection University Hospital of Cologne Center for Molecular Medicine Cologne Germany 2020-04-30 2020-10-31 KICC19, NCT04341168 Phase Not Applicable Not yet recruiting 1 6 Months 160 Centina Kuiper-Makris, Christoph Hünseler, PD Dr., Esther Mahabir-Brenner, Prof. Dr., Florian Klein, PD Dr., Jan Rybniker, PD Dr. Dr., Julia Fischer, Dr., Katja Höpker, PD Dr., Lutz Weber, Prof. Dr., Miguel A Alejandre Alcazar, Prof. Dr. Dr., Robert W Koerner, Dr., Robert W Körner, Dr., Rolf Kaiser, Dr., Saleta Sierra - Aragón, PD Dr., Tom Schildberg, Dr. 2020-04-15
The Impact of Family-Based Empowerment Model on Stress, Anxiety and Satisfaction Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection empowerment training sessions alone Torbate-Heidaria University of Medical Sciences Iran 2020-03-20 IR.THUMS.REC.1398.060, IRCT20180429039463N2 Phase Not Applicable Recruiting 1 30 mohammad namazi nia, محمد نمازی نیا 2020-04-14
WHIP COVID-19: Will Hydroxychloroquine Impede or Prevent COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Henry Ford Health System US 2020-04-07 2021-04-30 1410401, NCT04341441, WHIP COVID-19 Phase 3 Clinical Recruiting 0 12 Months 3000 Dee Dee Wang, MD, John McKinnon, MD, Laurie Nightengale, MD, William W O'Neill, MD 2020-04-16
BURDENCOV: Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers Coronavirus disease 19 infection, Influenza virus infection, Post traumatic stress disorder, Viral pneumonia burnout alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-09 2021-12-31 APHP200389, BURDENCOV, NCT04341519 Phase Not Applicable Not yet recruiting 1 20 Months 1464 Elie AZOULAY, MD PhD, Matthieu RESCHE-RIGON, MD PhD, Nancy KENTISH-BARNES, MD PHD, Nancy KENTISH-BARNES, PhD, matthieu resche-rigon, MD-PhD 2020-04-15
Evaluation the effects of Favipiravir in COVID-19 patients Coronavirus disease 19 infection favipiravir (Toliddaru-Sobhan Oncology company, Iran) alone, standard and supportive care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shaheed Beheshti Medical University Iran 2020-04-05 IR.SBMU.RETECH.REC.1399.011, IRCT20151227025726N14 Phase 3 Clinical Recruiting 1 84 Afshin Zarghi, Ali Saffaei, Farzaneh Dastan, Hossein Vahidi, Payam Tabarsi 2020-04-14
CTII-nCoV: A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) Coronavirus disease 19 infection Ad5-nCoV alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Institute of Biotechnology the Academy of Military Medical Sciences PLA CanSino Biologics Inc, Hubei Provincial Center for Disease Control and Prevention, Jiangsu Province Centers for Disease Control and Prevention, Zhangnan Hospital China 2020-04-12 2021-01-31 CTII-nCoV, JSVCT089, NCT04341389 Phase 2 Clinical Recruiting 2 9 Months 500 Fengcai Zhu, MD, Wenjuan Wang, MD, Zhao Wang, MD 2020-04-16
COVID19-COVIDornase: Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2/COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome dornase alfa alone Deoxyribonuclease I stimulator, Deoxyribonuclease stimulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Foundation Adolphe De Rothschild France 2020-04-10 2020-001492-33, CGE_2020_9, COVID19-COVIDornase Phase 3 Clinical No longer recruiting 1 100 Clinical Research Director 2020-04-15
Evaluation the efficacy of hot foot-bath on COVID-19 Coronavirus disease 19 infection hot foot bath alone Shaheed Beheshti Medical University Iran 2020-04-15 IR.SBMU.RETECH.REC.1399.029, IRCT20180923041093N5 Phase 3 Clinical Recruiting 1 60 Afshin Zarghi, Fatemeh sadat Hasheminasab, Roshanak Mokaberinejad 2020-04-15
BIOCOVU: Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-08-31 2020-A00906-33, 2020_33, BIOCOVU, NCT04341792 Phase Not Applicable Not yet recruiting 1 4 Months 1000 Delphine Garrigue, MD 2020-04-14
A clinical study of elsulfavirine in combination with favipiravir for the treatment of severe COVID-19 infection Coronavirus disease 19 infection elsulfavirine plus favipiravir HIV-1 reverse transcriptase inhibitor, Non-nucleoside reverse transcriptase inhibitor, RNA polymerase inhibitor Viriom Inc Phase Not Applicable Planned 0 2020-04-14
Study of TJ-003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) Coronavirus disease 19 infection TJM-2 alone GM-CSF ligand inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) I-Mab Biopharma US 2020-04-11 2020-09-30 NCT04341116, TJ003234COV201 Phase 1/Phase 2 Clinical Recruiting 0 5 Months 144 Chadi A. Hage, MD, Claire Xu, MD, PhD, Joseph Kim, MD, Julia Garcia-Diaz, MD, Robert Jeanfreau, MD, US Site Head 2020-04-17
A first in human trial to evaluate spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences for the treatment of COVID-19 patients Coronavirus disease 19 infection spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences alone Coronavirus spike glycoprotein inhibitor Brii Biosciences, The Third People’s Hospital of Shenzhen, Tsinghua University 2020-09-30 Phase 1 Clinical Planned 0 2020-04-13
Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic Coronavirus disease 19 infection telephone consultation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universite Pierre et Marie Curie France 2020-03-16 2020-06-15 GREEN GRC01, NCT04341714 Phase Not Applicable Recruiting 1 3 Months 400 Camille Chesnel, MD, Gérard Amarenco, PhD 2020-04-13
CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection Coronavirus disease 19 infection, Viral pneumonia anakinra alone Type I IL-1 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-30 2020-12-31 APHP200375-5, CORIMUNO-ANA, NCT04341584 Phase 2 Clinical Not yet recruiting 1 8 Months 240 Matthieu Resche-Rigon, MD, PhD, Xavier Mariette, MD, PhD 2020-04-15
NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Coronavirus disease 19 infection nitric oxide (NO) alone, standard of care alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Nu-Med Plus, Xijing Hospital US 2020-03-21 2022-04-01 COVID19 NOGAS MILD, NCT04290858, NCT04305457, NOGAS MILDCOVID-19, NoCovid Phase 2 Clinical Recruiting 0 24 Months 240 Lei Chong, Lorenzo Berra, Lorenzo Berra, MD 2020-04-14
University of Utah COVID-19 Hydrochloroquine Trial Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Utah US 2020-04-14 2023-04-30 IRB_00131893, NCT04342169 Phase 2 Clinical Recruiting 0 36 Months 400 Adam Spivak, MD, Christina Pacchia, PhD 2020-04-17
COVID-SER: Assessment of Serological Techniques for Screening Patients Regarding COVID-19 Coronavirus disease 19 infection serological tests alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospices Civils De Lyon 2020-04-09 2020-09-09 69HCL20-0329, COVID-SER, NCT04341142 Phase Not Applicable Not yet recruiting 0 5 Months 400 Jean-Baptiste Mr FASSIER, Dr 2020-04-14
Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Istanbul University-Cerrahpasa Turkey 2020-04-10 2020-07-01 GPA1347, NCT04342208 Phase Not Applicable Not yet recruiting 1 2 Months 500 Ayşe Zengin Alpözgen, Gamze Polen Aksimsek 2020-04-13
Hydroxychloroquine Versus Nitazoxanide in Patients With COVID-19 Coronavirus disease 19 infection hydroxychloroquine plus nitazoxanide Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Materno-Perinatal Hospital of the State of Mexico Mexico 2020-04-06 2020-12-30 2020-03-681, NCT04341493 Phase 4 Clinical Recruiting 1 8 Months 86 Acela Marle Santamaria Benhumea, PhD., Hugo Mendieta Zeron, Hugo Mendieta Zeron, PhD, Hugo Mendieta Zeron, PhD., José Meneses Calderon, MD 2020-04-14
COVIDeHPAD: Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease Coronavirus disease 19 infection telehealth applications alone Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Limoges 2020-04-30 2020-09-30 87RI20_0013, COVIDeHPAD, NCT04337788 Phase Not Applicable Not yet recruiting 0 5 Months 200 Achille TCHALLA, MD 2020-04-14
Effects of DPP4 Inhibition on COVID-19 Coronavirus disease 19 infection, Non-insulin dependent diabetes insulin plus linagliptin Dipeptidyl peptidase IV inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Miami US 2020-04-30 2020-09-30 20200384, NCT04341935 Phase 4 Clinical Not yet recruiting 0 5 Months 20 Gianluca Iacobellis, MD PhD 2020-04-17
Video-Based Exercises and Well-Being During Social Isolation Coronavirus disease 19 infection, Influenza virus infection Video based aerobic exercise alone Healthy volunteers accepted, Young Adults (18-44 yrs) Biruni Üniversitesi Istanbul University-Cerrahpasa Turkey 2020-04-06 2020-06-30 NCT04335851, PHYSICAL ACTIVITY PROJECT Phase Not Applicable Not yet recruiting 2 2 Months 30 Ayse Zengin Alpozgen, Assistant Professor, PhD, Ayşe Zengin Alpözgen, Assistant Professor, PhD, Begum Kara Kaya, MSc, Esma Nur Kolbaşı, MSc, Eylül Pınar Kısa, MSc, Gamze Polen Şimşek, MSc, Pelin Tiryaki, MSc 2020-04-13
SHARP COVID-19: Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-risk Population (SHARP): a Cluster-randomized, Controlled Trial Coronavirus disease 19 infection hydroxychloroquine sulfate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tan Tock Seng Hospital Duke-NUS Graduate Medical School, Dutch Ministry of Health, Welfare and Sport, National Center for Infectious Diseases, Saw Swee Hock School of Public Health, Singapore Clinical Research Institute, Singapore Eye Research Institute Singapore 2020-04-30 2020-10-31 2020/00402, NCT04342156, SHARP COVID-19 Phase 3 Clinical Not yet recruiting 1 6 Months 3000 Rupesh Agrawal, MD 2020-04-14
Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19 Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia Ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Intercommunal Creteil France 2020-03-31 2020-09-30 COVID-ECHO, NCT04341766 Phase Not Applicable Recruiting 7 6 Months 200 Antoine Luchez, MD, Ayman KHEIR, MD, Gilles MANGIAPAN, MD, Gilles Mangiapan, MD, Marie Coudurier, MD, Sophie Laroumagne, MD, Thomas Flament, MD, Yannick Simonneau, MD 2020-04-14
CORIMUNO-VIRO: Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO Coronavirus disease 19 infection, Lung disease, Viral pneumonia standard of care alone, Variable regimens including azithromycin , hydroxychloroquine , sarilumab IL-6 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris France 2020-04-11 2020-07-31 APHP200375-3, CORIMUNO-VIRO, NCT04341870 Phase 2/Phase 3 Clinical Recruiting 4 3 Months 60 David Saadoun, MD PhD, Matthieu Resche-Rigon, MD PhD 2020-04-15
A clinical trial to assess MN-166 in the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients Coronavirus disease 19 infection, Respiratory distress syndrome ibudilast (oral, neuropathic pain/opiate dependence/neurodegeneration/TBI/drug dependence), MediciNova alone IL-6 receptor antagonist, Interleukin-1 beta ligand inhibitor, Macrophage migration inhibitory factor inhibitor, PDE 10 inhibitor, PDE 4 inhibitor, TLR-4 antagonist, TNF alpha ligand inhibitor Yale School of Medicine US Phase Not Applicable Planned 0 Dr. Geoffrey Chupp, Dr. Insoo Kang, r. Maor Sauler 2020-04-13
Evaluation of the efficacy of oral 25-hydroxyvitamin D3 on COVID-19 Coronavirus disease 19 infection 25-hydroxyvitamin D3 alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tehran University of Medical Sciences Iran 2020-04-14 IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N2 Phase 3 Clinical Recruiting 2 540 Arash Shirvani, Mohammadali Sahraian, Zhila Maghbooli 2020-04-15
Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS Coronavirus disease 19 infection, Respiratory distress syndrome plasma alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-13 IR.MUMS.REC.1399.055, IRCT20200409047007N1 Phase 2 Clinical Recruiting 1 32 Dr Abolghasem Allahyari, Dr Mohsen Seddigh Shamsi 2020-04-14
Effect of minocycline on COVID-19 Coronavirus disease 19 infection minocycline alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.053, IRCT20081019001369N4 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri 2020-04-14
MultiCov: Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia Combined use of a respiratory broad panel multiplex PCR and procalcitonin alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux de Paris bioMerieux SA France 2020-04-30 2020-08-31 2020-001324-33, APHP200392, MultiCov, NCT04334850 Phase Not Applicable Not yet recruiting 1 4 Months 194 Guillaume VOIRIOT, MD, Muriel FARTOUKH, PU-PH MD PHD 2020-04-14
Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19) Coronavirus disease 19 infection telerehabilitation exercise alone Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) Istanbul University-Cerrahpasa Turkey 2020-04-20 2020-07-31 002, NCT04334434 Phase Not Applicable Not yet recruiting 1 3 Months 30 Ayse Zengin Alpözgen, Ass.Prof.PhD, Ayse zengin alpozgen, Ece Acikbas, MSc, Eren Avcil, MSc, Fulya Demirhan, MSc, Kubra Koce, MSc, Kubra Koce, MSc PT, Kubra Sagir, MSc 2020-04-17
Al-COVE: AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience Coronavirus disease 19 infection, Sepsis, Transplant rejection AlloSure dd-cf DNA test alone CareDx Inc 2020-04-01 2021-03-01 AL-COVE, Al-COVE, NCT04341103 Phase Not Applicable Not yet recruiting 0 11 Months 500 Alana Burns 2020-04-14
COVA: A phase II/III study to assess the efficacy and the safety of Sarconeos (BIO-101) in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome 20‐hydroxyecdysone (oral, sarcopenia/sarcopenic obesity/Duchenne muscular dystrophy), BIOPHYTIS alone Proto-oncogene Mas agonist BIOPHYTIS Belgium, US, France COVA Phase 2/Phase 3 Clinical Planned 2 2020-04-13
The effect of elderberry syrup against COVID-19 symptoms Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Lymphocytopenia, Myalgia elderberry extract syrup alone, standard treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.045, IRCT20200406046965N1 Phase 2 Clinical Not yet recruiting 1 40 Mohammad Javad Dehghan Nayyeri, Seyed Ahmad Emami 2020-04-14
Non-contact ECG Sensor System for COVID-19 Coronavirus disease 19 infection non-contact ECG alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Northwestern Medicine US 2020-04-15 2020-09-15 20-0407, NCT04341506 Phase Not Applicable Not yet recruiting 0 5 Months 100 Andrew Gostine, Andrew Gostine, MD 2020-04-14
Remdesivir in treatment of COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection Variable regimens including atazanavir , chloroquine phosphate , hydroxychloroquine sulfate , lopinavir + ritonavir , remdesivir , ribavirin HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, RNA polymerase modulator Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-03-20 IR.TUMS.VCR.REC.1398.1076, IRCT20171122037571N2 Phase 2/Phase 3 Clinical Recruiting 12 120 Aydin PoorKazemi, Azar Haddadi, Farhang BabaMahmoudi, Farzin Khorvash, Hamed Hosseini, Ilad Alavi Darazam, Mansooreh Momen-Heravi, Mehrdad Hasibi, Mohammad Reza Salehi, Mostafa Ghanei, Payam Tabarsi, Rozita Khodashahi, Saeed Kalantari 2020-04-14
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19 Cancer, Coronavirus disease 19 infection chemotherapy alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tongji Hospital China 2020-04-10 2020-07-10 2020-TJ-COVID-19, NCT04341480 Phase Not Applicable Not yet recruiting 1 3 Months 207 Qinglei Gao, Qinglei Gao, Dr. 2020-04-14
The effect of SOVODAK in the treatment of COVID-19 patients Coronavirus disease 19 infection training alone, Variable regimens including Sovodak (sofosbuvir + daclatasvir) , azithromycin , hydroxychloroquine , naproxen , pantoprazole H+ K+ ATPase inhibitor Mazandaran University of Medical Sciences Iran 2020-04-08 IR.MAZUMS.REC.1399.017, IRCT20200403046926N1 Phase 3 Clinical Recruiting 1 60 Fatemeh Roozbeh 2020-04-14
SIC: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia methylprednisolone (Pfizer) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Ramón y Cajal Spain 2020-04-01 2020-001307-16, SIC, SIC Phase 3 Clinical Recruiting 1 104 Anabel Sánchez 2020-04-14
DEFACOVID: Defibrotide as prevention and treatment of respiratory distress and cytokine release syndrome of COVID-19 Coronavirus disease 19 infection, Respiratory distress syndrome defibrotide (iv, veno-occlusive disease), Gentium alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) Instituto de Salud Carlos III Spain 2020-04-08 2020-08-08 2020-001409-21, DEFACOVID, IMIB-DFC-2020-02, NCT04348383 Phase 2b Clinical Recruiting 2 4 Months 120 José M. Moraleda, MD, LOLA SERNA GUIRAO 2020-04-17
Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection Coronavirus disease 19 infection azithromycin plus hydroxychloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Asociación Instituto de Investigación Sanitaria BioCruces Spain 2020-04-07 2020-001606-33, HIACO-19 Phase 3 Clinical Recruiting 1 132 Epidemiologist 2020-04-14
TACROVID: Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury Coronavirus disease 19 infection, Lung injury methylprednisolone plus tacrolimus (oral sustained-release), Astellas Calcineurin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hospital Universitari de Bellvitge Institut Investigació Biomèdica Bellvitge Spain 2020-04-01 2020-07-01 2020-001445-39, NCT04341038, TACRO-BELL-COVID, TACROVID Phase 3 Clinical Recruiting 1 3 Months 84 Arnau Antolí, MD, Xavier Corbella, MD, PhD, Xavier Solanich, MD 2020-04-16
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases Coronavirus disease 19 infection, Liver cirrhosis Breath Analysis Test alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mayo Clinic FLORIDA US 2019-09-10 2021-12-31 19-001971, NCT04341012 Phase Not Applicable Recruiting 0 27 Months 120 Joanna Roopkumar, Robert Brannock, Tushar Patel, Tushar Patel, MBChB 2020-04-14
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury Coronavirus disease 19 infection, Heart injury, Hemophagocytic lymphohistiocytosis, Respiratory distress syndrome immunophenotyping alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Barts and The London NHS Trust Queen Mary University of London UK 2020-04-10 2020-06-10 282289, NCT04340921 Phase Not Applicable Not yet recruiting 1 2 Months 140 Daniel E Harding, BM BCh, Federica Marelli-Berg, PhD, Sam (Saidi) Mohiddin, MD 2020-04-14
HOME-CoV: Hospitalization or Outpatient Management of Patients With a SARS-CoV-2 Infection Coronavirus disease 19 infection HOME-CoV rule implementation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers Belgium, Monaco, France 2020-04-09 2020-06-01 2020-A00831-38, HOME-CoV, NCT04338841 Phase Not Applicable Recruiting 28 1 Month 4000 Andréa PENALOZA, Anthony CHAUVIN, Christian BRICE, MD, Delphine DOUILLET, Francis COUTURAUD, GHUYSEN Alexandre 2020-04-14
REPLACECOVID: Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 Cardiovascular disease, Coronavirus disease 19 infection, Hypertension, Renal injury, Respiratory disease Angiotensin Converting Enzyme Inhibitors alone, Angiotensin Receptor Blockers alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Pennsylvania 2020-03-31 2020-12-31 842810, NCT04338009, REPLACECOVID Phase Not Applicable Not yet recruiting 0 9 Months 152 James Brian Byrd, MD, Jordana B. Cohen, MD, MSCE, Julio A Chirinos, Roberto Viau Colindres, Thomas C. Hanff, MD, MPH, Vicente Corrales-Medina, MD, PhD 2020-04-14
AspiFlu: Aspergillosis in patients with severe influenza or coronavirus Coronavirus disease 19 infection, Influenza virus infection, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) St George's University Hospitals NHS Foundation Trust Gilead Sciences Inc UK 2019-07-06 2021-08-05 AspiFlu, CPMS 43440, IRAS 271269, ISRCTN51287266 Phase Not Applicable Recruiting 4 25 Months Dr Tihana Bicanic, Dr Youngs 2020-04-13
Multicenter, randomized, controlled, parallel study to study the effectiveness and safety of hydroxychloroquine (ZAO Biocom, Russia) in patients with a new coronavirus infection COVID-19 Coronavirus disease 19 infection hydroxychloroquine, Biocom alone JSC Biocom Russian Federation 2020-04-09 2021-03-30 ST-23032020-HQBIO Phase 3 Clinical Status not specified 1 11 Months 120 2020-04-13
Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation Coronavirus disease 19 infection lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Griffith University, Royal Brisbane & Women's Hospital Australia 2020-04-20 ACTRN12620000438954 Phase Not Applicable Not yet recruiting 4 60 A/Prof Jennifer Paratz 2020-04-14
C4: Chloroquine Chemorophylaxis Countermeasure against COVID-19 Coronavirus disease 19 infection, SARS coronavirus infection chloroquine phosphate alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Australian Defence Force Malaria and Infectious Disease Institute Defence Materiel Technology Centre (DMTC) Australia 2020-03-30 2020-05-11 ACTRN12620000417987, C4 Phase 4 Clinical Not yet recruiting 1 1 Month 680 Dr Scott Hahn, Prof Dennis Shanks 2020-04-14
VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic Anxiety disorder, Coronavirus disease 19 infection, Depression Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitätsklinikum Erlangen Psychosomatische und Psychotherapeutische Abteilung Universitatsklinikum Erlangen, Universitätsklinikum Bonn Klinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Ulm Psychosomatik Germany 2020-04-20 133_20 B, DRKS00021268, VOICE Phase Not Applicable Not yet recruiting 5 2000 Andrea Borho, Eva Morawa 2020-04-13
Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers Coronavirus disease 19 infection, Psychiatric disorder Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The National Institute of Mental Health National Institutes of Health Clinical Center US 2020-04-20 2022-04-01 20-M-N085, 999920085, NCT04339790 Phase Not Applicable Recruiting 0 23 Months 5000 Alison Gibbons, Joyce Y Chung, M.D. 2020-04-16
HCQINRLGII: Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals Coronavirus disease 19 infection Bisolvon plus Plaquenil Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Rehabilitacion Mexico 2020-04-10 2020-07-10 20/20, HCQINRLGII, NCT04340349 Phase 0 Clinical Not yet recruiting 1 3 Months 100 Julio Granados Montiel 2020-04-13
NODS-Cov2: Nosocomial Dissemination Risk of SARS-Cov2 Coronavirus disease 19 infection Assistance Publique Hopitaux de Paris France 2020-04-13 2020-06-15 APHP200417, NCT04339881, NODS-Cov2 Phase Not Applicable Not yet recruiting 1 2 Months 100 Bich-Tram Huynh, Didier Guillemot, Didier Guillemot, Pr 2020-04-13
COVID-19 Risk Stratification Coronavirus disease 19 infection risk score validation alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Brigham & Women's Hospital US 2020-03-01 2020-04-15 2020P000944, NCT04339387 Phase Not Applicable Recruiting 0 1 Month 1500 David Levine, David Levine, MD, David M Levine, MD MPH MA 2020-04-13
FRENCH CORONA: French, Multicenter, Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire de Nimes France 2020-04-03 2021-04-30 2020-A00797-32, FRENCH CORONA, NCT04340466 Phase Not Applicable Recruiting 1 12 Months 220 Anissa MEGZARI, CLAIRE ROGER, CLAIRE ROGER, MD, PhD, Claire Roger, MD, PhD 2020-04-15
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection Coronavirus disease 19 infection atovaquone plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) HonorHealth Research Institute US 2020-04-30 2021-04-30 HRI-COVID-19-ANTI-MALARIAL-001, NCT04339426 Phase 2 Clinical Not yet recruiting 0 12 Months 25 Heather Lane, Karen Lewandowski, RN, Michael Gordon, MD 2020-04-16
Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt (COVID-19) Coronavirus disease 19 infection Assiut University Egypt 2020-05-01 2020-07-30 COVID-19 IN EGYPT, NCT04339322 Phase Not Applicable Not yet recruiting 2 2 Months 200 Haidi Karam 2020-04-13
Multicentric, Retrospective, Observational Study of Thoracic Scanner Performance in COVID Screening Coronavirus disease 19 infection, Lung injury thoracic CT scan alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation 2020-04-30 2020-11-30 NCT04339686, POWER-COVID_CT Phase Not Applicable Not yet recruiting 0 7 Months 56000 Guillaume HERPE 2020-04-14
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection Acute lung injury, Coronavirus disease 19 infection, Hypoxia, Respiratory failure losartan alone, standard of care alone Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sharp HealthCare US 2020-03-27 2020-12-31 2003902, COVID-ARB, NCT04340557 Phase 4 Clinical Recruiting 0 9 Months 200 Adriana Valdez-Hernandez, RN, Cary Murphy, RN, George Sakoulas, MD, Katie Miller, Matthew Geriak, Matthew Geriak, PharmD 2020-04-13
Evaluation of the efficacy of Oral 25-hydroxyvitamin D3 on COVID-19 Coronavirus disease 19 infection 25-hydroxyvitamin D3, Dishmen alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tehran University of Medical Sciences Iran 2020-04-15 IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N1 Phase 3 Clinical Recruiting 1 260 Arash Shirvani, Mohammadali Sahraian, Mohammadali Sahraian, Research Deputy, Zhila Maghbooli 2020-04-15
COVID-19 Convalescent Plasma Coronavirus disease 19 infection COVID-19 convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Chicago US 2020-04-10 2021-12-31 IRB20-0523, NCT04340050 Phase 0 Clinical Recruiting 0 20 Months 10 Maria Lucia Madariaga, Maria Lucia Madariaga, MD 2020-04-16
Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia CVVH machine alone, Low flow ECMO driving alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Peking Union Medical College Hospital China 2020-03-03 2020-10-15 LOW FLOW-ECMO BY CVVH IN NCP, NCT04340414 Phase Not Applicable Recruiting 2 7 Months 10 Huaiwu He, MD, Wei Cheng, MD, Xiang Zhou, MD, Yun Long, Yun Long, MD 2020-04-13
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy Coronavirus disease 19 infection Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tabula Rasa HealthCare Inc US 2020-04-07 2021-04-06 COVID-PACE-2020-001, NCT04339634 Phase Not Applicable No longer recruiting 0 12 Months 12123 Veronique Michaud, PhD 2020-04-15
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) Coronavirus disease 19 infection point-of-care ultrasonography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Minnesota US 2020-04-15 2020-10-31 NCT04339998, STUDY00009429 Phase Not Applicable Not yet recruiting 0 6 Months 500 Jon Kirsch, MD, Matthew Yocum, MD 2020-04-13
Eating Habits of Adults During the Quarantine Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Eastern Mediterranean University Cyprus Science University Cyprus, Turkey 2020-04-10 2020-05-31 NCT04339842, NUTR2020 Phase Not Applicable Recruiting 2 1 Month 400 Eliz Arter, Eliz Arter, MSc, Zalihe Yarkiner, PhD 2020-04-16
Max COVID19 Study Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry Max Healthcare Institute Ltd, India India 2020-04-02 2020-06-30 COVID-19/MHC/2020, NCT04339608 Phase Not Applicable Recruiting 1 2 Months 10000 Samreen Siddiqui, PhD, Sandeep Budhiraja, MRCP (U.K), MD, Sujeet Jha, MRCP (U.K) 2020-04-13
ONCOVID: Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic Anxiety disorder, Cancer, Coronavirus disease 19 infection, Mood disorder Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universitair Ziekenhuis Gent Belgium 2020-03-30 2020-09-30 BC-07505-LGE, NCT04340219, ONCOVID Phase Not Applicable Recruiting 1 6 Months 180 Emiel De Jaeghere, MD, Hannelore Denys, Hannelore Denys, MD, PhD, Heini Kanervo, RN 2020-04-13
AZIQUINE-ICU: Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomized, Controlled Trial Coronavirus disease 19 infection, Respiratory failure azithromycin plus hydrochloroquine Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Charles University Faculty Hospital Olomouc, General University Hospital, Prague, Masaryk Hospital Usti nad Labem, St. Anne's University Hospital Brno, Czech Republic, The Faculty Hospital Na Bulovce, University Hospital Motol, University Hospital Pilsen Czech Republic 2020-04-20 2022-06-30 2020-001456-18, AZIQUINE-ICU, AZIQUINE-ICU-25032020, NCT04339816 Phase 3 Clinical Not yet recruiting 1 26 Months 240 Frantisek Duska 2020-04-14
Evaluation of Serum Zinc Levels Response to Treatment of Covid-19 Positive Patients Coronavirus disease 19 infection Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-03-20 2020-05-03 NCT04339556, ZINCCOVID19 Phase Not Applicable No longer recruiting 1 1 Month 25 Pınar Yalcin bahat 2020-04-13
A Study on Melatonin and Vitamin C and Zinc Efficacy in Patients With COVID-19 Coronavirus disease 19 infection Variable regimens including ascorbic acid , melatonin , zinc sulfate Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Semnan University of Medical Sciences Iran 2020-04-07 IR.SEMUMS.REC.1399.005, IRCT20151228025732N52 Phase 3 Clinical Recruiting 1 20 Fatemeh Ehsani, Mahboubeh Darban 2020-04-14
The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation Coronavirus disease 19 infection, Injury FAST+ examination alone, computed tomography alone, lung ultrasound alone Healthy volunteers accepted University of Colorado, Denver, US US 2020-05-01 2021-05-01 20-0751, NCT04340479 Phase Not Applicable Not yet recruiting 0 12 Months 20 Jose L Diaz-Miron, MD 2020-04-13
Evaluating the effect of marshmallow and licorice on COVID 19 patients Coronavirus disease 19 infection marshmallow and licorice mixed herbal drink intake alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ahvaz University of Medical Sciences Iran 2020-04-09 IR.AJUMS.REC.1399.012, IRCT20200404046937N1 Phase 3 Clinical Recruiting 3 60 Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani 2020-04-13
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia Coronavirus disease 19 infection, Viral pneumonia conventional treatment alone, human umbilical cord-derived MSCs alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Wuhan Puren Hospital Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Shanghai University China 2020-02-01 2020-06-30 NCT04339660, PR20200402 Phase 1/Phase 2 Clinical Recruiting 1 5 Months 30 Yan Liu, MD, Yue Zhu 2020-04-17
Physical Activity During Social Isolation Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul University Turkey 2020-04-30 2020-06-30 30042020-1, NCT04339491 Phase Not Applicable Not yet recruiting 1 2 Months 500 Ayse Zengin Alpozgen, PhD, Saliha Gurdal Karakelle, Saliha Gurdal Karakelle, MSc 2020-04-10
COMIHY: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital Tubingen Bernhard-Nocht-Institute for Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf Germany 2020-04-10 2022-09-30 COMIHY, COMIHY, NCT04340544 Phase 3 Clinical Not yet recruiting 1 29 Months 2700 Diane Egger-Adam, Dr., Peter Kremsner, Prof. 2020-04-13
Safety and Efficacy of Baricitinib for COVID-19 Coronavirus disease 19 infection, Viral pneumonia baricitinib alone Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Colorado, Denver, US US 2020-04-30 2020-10-31 20-0738, NCT04340232 Phase 2/Phase 3 Clinical Not yet recruiting 0 6 Months 80 Angela Rachubinski, PhD, Joaquin Espinosa, PhD 2020-04-13
Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences Coronavirus disease 19 infection medications alone, Fenugreek syrup plus Viroherb capsule Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Tehran University of Medical Sciences Iran 2020-04-05 IR.TUMS.VCR.REC.1399.099, IRCT20200402046923N1 Phase 3 Clinical Recruiting 3 110 Ali Asadollahi-Amin, Dr. Mohammad Ali Sahraeian, Hadise Hosami Roodsari, Roja Rahimi, Saeed Reza Jamali Moghaddam 2020-04-13
TCOutpatient: TXA and Coronavirus 2019 (COVID-19) in Outpatients Coronavirus disease 19 infection enoxaparin sodium plus tranexamic acid Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alabama at Birmingham US 2020-04-15 2020-10-30 NCT04338074, TCOutpatient, TXACOVID1 Phase 2 Clinical Not yet recruiting 0 6 Months 100 Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD 2020-04-13
A first-in-human, phase I study of CORVax12 for the prevention of COVID-19 infection Coronavirus disease 19 infection APOLLO electroporation device alone, DNA vaccine targeting SARS-CoV-2 spike protein + tavokinogene telseplasmid (APOLLO electroporation, COVID-19), OncoSec Medical alone IL12 gene stimulator Healthy volunteers accepted Providence Cancer Institute at Providence Hospital OncoSec Medical Inc US Phase 1 Clinical Planned 0 Rom Leidner, MD 2020-04-09
CLOCC: Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 Coronavirus disease 19 infection camostat mesylate plus hydroxychloroquine Serine protease inhibitor, Trypsin inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Heinrich Heine Universitat Dusseldorf Hospital Schwabing Munich, Germany, Klinikum St Georg, Missioklinik, Wuerzburg, Germany, University Hospital Frankfurt, Universitätsklinikum Hamburg-Eppendorf Germany 2020-06-01 2021-12-31 CLOCC, CLOCC-2020, NCT04338906 Phase 4 Clinical Not yet recruiting 1 19 Months 334 2020-04-10
TCInpatient: Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients Coronavirus disease 19 infection enoxaparin sodium plus tranexamic acid Low molecular weight heparin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Alabama at Birmingham US 2020-04-15 2020-12-15 NCT04338126, TCInpatient, TXACOVID2 Phase 2 Clinical Not yet recruiting 0 8 Months 60 Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD 2020-04-13
Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection Cconventional medication alone, umbilical cord derived mesenchymal stem cells alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Huangshi Hospital of Traditional Chinese Medicine China 2020-02-01 2020-12-02 ChiCTR2000031494 Phase 1 Clinical Recruiting 1 10 Months 36 Feng Ganzhu, Leng Nannan 2020-04-10
Efficacy of Kelofan syrup on COVID-19 Coronavirus disease 19 infection Kelofan syrup alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ardabil University of Medical Sciences Iran 2020-04-09 IR.ARUMS.REC.1399.009, IRCT20200405046960N1 Phase 1/Phase 2 Clinical Recruiting 2 15 Dr.Shahab Bohlooli, Ramin Nasimi Doost Azgomi 2020-04-10
CAP-1002 in Severe COVID-19 Disease Coronavirus disease 19 infection CAP-1002 alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Capricor Inc US CAP-1002-COVID-19, NCT04338347 Phase Not Applicable Recruiting 0 Khaled Alsabaawi, Mitch Gheoghiu, MD, Paula Williams, MS, Raj Makkar, MD, Siegfried Rogy, PhD 2020-04-10
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-19 Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia nintedanib alone CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Tongji Hospital China 2020-04-02 2020-08-01 HUILANZ ZHANG, NCT04338802 Phase 2 Clinical Not yet recruiting 1 4 Months 96 Huilan Zhang, Huilan Zhang, PD, Xianglin Yuan, PD 2020-04-10
ASCOT: To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care Coronavirus disease 19 infection hydroxychloroquine alone, lopinavir + ritonavir alone, hydroxychloroquine plus lopinavir + ritonavir HIV protease inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Melbourne Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Royal Brisbane & Womens Hospital Research Foundation, The Pratt Foundation, University of Queensland New Zealand, Australia 2020-04-10 ACTRN12620000445976, ANZCTR12620000445976, ASCOT Phase 3 Clinical Not yet recruiting 65 2500 A/Prof Steven Tong 2020-04-14
Effect of methylprednisolone in treatment of COVID-19 patients Coronavirus disease 19 infection methylprednisolone alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shiraz University of Medical Sciences Iran 2020-04-14 IR.SUMS.REC.1399.014, IRCT20200204046369N1 Phase 2/Phase 3 Clinical Recruiting 2 48 Dr. Mohsen Moghadami, Mohammad-Javad Fallahi, Mohsen Moghadami 2020-04-14
Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Royal Brisbane & Women's Hospital Australia 2020-03-31 ACTRN12620000447954, ANZCTR12620000447954 Phase 2 Clinical Recruiting 1 150 Prof Kevin B Laupland 2020-04-10
COVID-19 and Deep Venous Thrombosis Coronavirus disease 19 infection, Deep vein thrombosis Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Jessa Hospital Belgium 2020-04-17 2020-12-30 JESSAH-COVID19-DVT, NCT04338932 Phase Not Applicable Not yet recruiting 1 8 Months 12 Bjorn Stessel, Dr, Ina Callebaut, dr, Stessel Björn, Dr 2020-04-10
Evaluation of Safety and efficacy of anti-inflammatory regimens in COVID-19 Coronavirus disease 19 infection Variable regimens including azithromycin , hydroxychloroquine , naproxen , pantoprazole , prednisolone H+ K+ ATPase inhibitor Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Bagheiat-allah University of Medical Sciences, Iran University of Medical Sciences Iran 2020-04-10 IR.BMSU.REC.1399.019, IRCT20200318046812N2 Phase 3 Clinical Recruiting 4 906 Ali Qazvini, Dr Abolfazl Mozafari, Dr Mahtab Niroomand, Dr Mariam Qaraati, Dr Seyed Abbas Motevalian, Mostafa Ghanei, Seyed Hassan Saadat, ََAli Qazvini 2020-04-11
NOCOVID: Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection Coronavirus disease 19 infection nitric oxide-based antiviral formulation (oral, COVID-19), Sanotize Research and Development alone, standard precautions alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) SaNOtize Research and Development Corp The Emmes Company, LLC Canada 2020-04-06 2020-09-30 COVID-CTP-01, NCT04337918, NOCOVID Phase 2 Clinical Not yet recruiting 1 5 Months 200 Chris Miller, Ph.D., Gilly Regev, Ph.D., Jeremy Road, MD 2020-04-16
Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms Coronavirus disease 19 infection, Viral pneumonia IMFLUNA herbal compound, HomaPharmed Pharmaceutical Company alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Institute of Medicinal Plants Iran 2020-03-30 IR.BMSU.REC.1399.036, IRCT20080901001157N16 Phase 1/Phase 2 Clinical Recruiting 1 60 Fallah Huseini Hasan, Mohammadreza Gholibeikian, Morteza Khairabadi, Reza Mohtashami 2020-04-11
PROTECT: Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: an RCT Coronavirus disease 19 infection azithromycin alone, oseltamivir alone, Variable regimens including azithromycin , hydroxychloroquine phosphate , hydroxychloroquine sulfate , oseltamivir Exo-alpha sialidase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Health Sciences Lahore Federal Task Force on Science & Technology Pakistan 2020-04-07 2020-11-30 12(06)/2016-COORD, NCT04338698, PROTECT Phase 3 Clinical Not yet recruiting 1 7 Months 500 Javed Akram, FRCP, Shehnoor Azhar, Shehnoor Azhar, MPH 2020-04-11
Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19) Coronavirus disease 19 infection Algomed alone, herbal tea intake alone, treatment protocol alone Semnan University of Medical Sciences Iran 2020-03-18 IR.SEMUMS.REC.1398.325, IRCT20151228025732N51 Phase Not Applicable Recruiting 1 60 Parviz Kokhaie, Rahimeh Eskandarian 2020-04-10
Evaluation the Effect of Teicoplanin in Patients With Coronavirus Disease Coronavirus disease 19 infection Variable regimens including atazanavir + ritonavir , hydroxychloroquine , lopinavir + ritonavir , teicoplanin HIV protease inhibitor Iran University of Medical Sciences Iran 2020-03-30 IR.IUMS.REC.1399.058, IRCT20161204031229N3 Phase 3 Clinical Recruiting 1 40 Azadeh Eshraghi, Azadeh Eshraghi، Saeed Kalantari, Dr.Motevalian, Saeed Kalantari 2020-04-10
NO COV-ED: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED Coronavirus disease 19 infection nitric oxide alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Massachusetts General Hospital US 2020-04-30 2022-04-30 2019P00XXXX, NCT04338828, NO COV-ED Phase 2 Clinical Not yet recruiting 0 24 Months 260 N. Stuart Harris MD MFA, N. Stuart Harris, MD, MFA 2020-04-10
SCOUT: Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study Coronavirus disease 19 infection, Viral pneumonia lung ultrasound alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Universiteit Hasselt Ziekenhuis Oost-Limburg Belgium 2020-04-13 2020-04-30 CTU2020032, NCT04338568, SCOUT Phase Not Applicable Recruiting 1 50 David Ruttens, MD, PhD, Inge Thijs, PhD, Marc Daenen, MD, Michiel J Thomeer, MD, PhD, Michiel J Thomeer, MD,PhD, Michiel Thomeer, MD, PhD, Michiel Thomeer, MD,PhD, Prof. dr. Michiel Thomeer 2020-04-16
Evaluation of the Effects of Ozone Therapy on Covid-19 Positive Patients Coronavirus disease 19 infection ozone therapy group (covid positive alone, azithromycin plus hydroxychloroquine Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-05-30 NCT04337866, OZONECOVID19 Phase Not Applicable No longer recruiting 2 1 Month 50 Pınar Yalcin bahat 2020-04-10
TRODVID-19: Dynamic Evaluation of COVID-19 Diagnostic Tests Coronavirus disease 19 infection antigenic rapid diagnostic orientation test (RODT) alone, polymerase chain reaction (PCR) alone, serological TROD alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre Hospitalier de Tourcoing France 2020-04-30 2020-10-31 NCT04337996, RIPH_2020_6, TRODVID-19 Phase Not Applicable Not yet recruiting 1 6 Months 176 Barthelemy LAFONDESMURS, MD, Pierre PATOZ, PharmD, Solange TREHOUX, PhD 2020-04-10
HOPEC: Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis Coronavirus disease 19 infection hydroxychloroquine (Amin Pharmaceutical company, Isfahan) alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Shahid Beheshti University of Medical Sciences Iran 2020-04-07 HOPEC, IR.SBMU.RETECH.REC.1399.026, IRCT20130917014693N10 Phase 3 Clinical Recruiting 1 100 Afshin Zarghi, Ali Saffaei, Minoosh Shabani, Omidvar Rezaiemirghaed, Zahra Sahraei 2020-04-13
Sleep COVID-19: Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic Coronavirus disease 19 infection, Insomnia online self-help leaflet alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Northumbria UK 2020-03-25 2022-04-06 ISRCTN43900695, Sleep COVID-19 Phase Not Applicable Recruiting 2 24 Months 75 Dr Elder 2020-04-10
JUPITER: Beat COVID-19 - Observational Trial Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Beat COVID LLC US 2020-04-06 2021-07-31 20200835, JUPITER, NCT04337762 Phase Not Applicable Recruiting 0 15 Months 100000 Hollis Ledbetter, Rama Jager, M.D. 2020-04-10
A phase I study of PittCoVacc for the potential prevention of COVID-19 infection Coronavirus disease 19 infection PittCoVacc alone University of Pittsburgh School of Medicine Phase 1 Clinical Planned 0 2020-04-09
Effect of berberine on COVID-19 Coronavirus disease 19 infection berberine hydrochloride (Mashhad University School of Pharmacy) alone, standard coronavirus treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Mashhad University of Medical Sciences Iran 2020-04-20 IR.MUMS.REC.1399.030, IRCT20081019001369N2 Phase 2 Clinical Not yet recruiting 1 40 Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi 2020-04-10
RuxCoFlam: Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation Coronavirus disease 19 infection, Hypoxia, Inflammatory disease, Respiratory disease, Viral pneumonia ruxolitinib alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University of Jena Germany 2020-05-01 2021-08-31 NCT04338958, RUXCOFLAM, RuxCoFlam Phase 2 Clinical Not yet recruiting 1 16 Months 200 Andreas Hochhaus, Prof. Dr., Christian Fabisch, Dr. 2020-04-13
The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Sheba Medical Center Israel 2020-04-05 2022-04-01 NCT04338672, SMC-20-7078-YZ-CTIL Phase Not Applicable Not yet recruiting 1 23 Months 1000000 Roi Anteby, MD 2020-04-09
A clinical trial to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection Coronavirus disease 19 infection allogeneic natural killer cells alone Green Cross LabCell South Korea Phase Not Applicable Planned 1 2020-04-09
Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy Coronavirus disease 19 infection COVID-surgRES questionaire alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) IRCCS AOU San Martino – IST Italy 2020-03-15 2020-05-01 COVID-ItaliansurgRES-SPIGC, COVID-SURGRES-ITALY, NCT04338945 Phase Not Applicable Recruiting 7 1 Month 1200 Fabio Barra 2020-04-13
A clinical study to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection Coronavirus disease 19 infection allogeneic natural killer cells alone Green Cross LabCell US Phase Not Applicable Planned 0 2020-04-09
POCUSCO: Point Of Care Ultrasonography for Risk-stratification of COVID-19 Patients Coronavirus disease 19 infection lung ultrasonography alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-04-06 2021-01-29 2020-A00782-37, NCT04338100, POCUSCO Phase Not Applicable Not yet recruiting 6 9 Months 300 Francis COUTURAUD, Dr, François MORIN, Dr, Karim TAZAROURTE, Pr, Laure BAUDIN, Dr, Louis SOULAT, Pr, Luc-Marie JOLY, Pr, Nicolas MARJANOVIC, Dr, Philippe LE CONTE, Pr, Pierre-Marie ROY, Pr, Thomas DELOMAS, Dr, Thomas FLAMENT, Dr 2020-04-10
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 Coronavirus disease 19 infection COVID-19 convalescent plasma alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Mayo Clinic Foundation US 20-003312, NCT04338360 Phase Not Applicable Recruiting 0 Michael Joyner, MD 2020-04-15
A Phase II efficacy Study of INO-4800 in COVID-19 infection Coronavirus disease 19 infection INO-4800 alone Inovio Pharmaceuticals Inc Phase 2 Clinical Planned 0 2020-04-15
LEOSS: Lean, European, Open Survey on SARS-CoV-2 (COVID-19) Coronavirus disease 19 infection rapid tests alone Deutsches Zentrum für Infektionsforschung Willy Robert Pitzer Stiftung Austria, France, Germany, Belgium, Spain, UK, Switzerland, Ireland, Bosnia and Herzegovina, Portugal, Iceland, Italy 2020-03-16 20-600, DRKS00021145, LEOSS Phase Not Applicable Recruiting 51 20000 Jorg Janne Vehreschild 2020-04-10
PiCCOVID: Hemodynamic Characteristics of Patients With SARS-CoV-2 Coronavirus disease 19 infection echocardiography alone, transpulmonary thermodilution alone, transpulmonary thermodilution system alone Hopital de Bicetre France 2020-04-15 2021-04-30 2020-A00793-36, NCT04337983, PiCCOVID Phase Not Applicable Not yet recruiting 1 12 Months 200 Xavier Monnet, Xavier Monnet, MD.PhD 2020-04-10
A clinical trial of anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin for the treatment of COVID-19 infection Coronavirus disease 19 infection anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin alone Octapharma AG Bio Products Laboratory Ltd, Biotest AG, CSL Ltd, LFB SA, Takeda Pharmaceutical Co Ltd Phase Not Applicable Planned 0 2020-04-09
Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients Coronavirus disease 19 infection chloroquine phosphate alone, standard therapy alone Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Command Hospital India 2020-04-13 CTRI/2020/04/024479 Phase 2 Clinical Not yet recruiting 1 32 SALIL GUPTA 2020-04-10
A phase I clinical study to assess IPT-001 for the prevention and treatment of COVID-19 infection Coronavirus disease 19 infection IPT-001 alone Coronavirus spike glycoprotein inhibitor, Nucleoprotein inhibitor INTELLiSTEM Technologies Inc 2020-09-30 Phase 1 Clinical Planned 0 2020-04-09
A clinical trial of ADDomer for the potential treatment of COVID-19 Coronavirus disease 19 infection ADDomer alone Imophoron Ltd Phase Not Applicable Planned 0 2020-04-09
A clinical trial to assess the efficacy and safety of tPA for the potential treatment of COVID-19-related respiratory failure Coronavirus disease 19 infection tissue plasma activator alone Beth Israel Deaconess Medical Center 2020-04-06 Phase Not Applicable Recruiting 0 Christopher D. Barrett, MD, Gyongyi Szabo 2020-04-09
Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy Coronavirus disease 19 infection, SARS coronavirus infection questionnaire alone, standard care alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Monash University, University of Melbourne Australia 2020-04-10 2021-12-31 ACTRN12620000449932 Phase Not Applicable Not yet recruiting 15 20 Months 200 Dr Clare Whitehead, Dr Miranda Davies-Tuck 2020-04-14
ZINC COVID study: Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection? Coronavirus disease 19 infection, SARS coronavirus infection Zinc Chloride alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Austin Health, University of Melbourne Australia 2020-04-09 ACTRN12620000454976, DT 62996/2020, ZINC COVID study Phase 1/Phase 2 Clinical Not yet recruiting 1 160 A/Prof Joseph Ischia A/Prof Joseph Ischia 2020-04-14
HOPE Study: Hydroxychloroquine for the Community-Based Treatment of COVID-19 Coronavirus disease 19 infection hydroxychloroquine alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Medical Research Institute of New Zealand Health Research Council of New Zealand New Zealand 2020-04-14 ACTRN12620000457943p, HOPE Study, MRINZ/20/01 Phase 2 Clinical Not yet recruiting 1 70 Dr Alex Semprini 2020-04-14
WriteForIBD: Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression evidenced-based 4-day writing program alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Crohn's & Colitis Australia, Deakin University Barwon Health Australia 2020-01-16 ACTRN12620000448943p, ANZCTR12620000457943, WriteForIBD Phase Not Applicable Not yet recruiting 4 154 A/Prof Antonina Mikocka-Walus 2020-04-10
A largest Chinese study on epidemiologic characteristics of Coronavirus Disease 2019 (COVID-19) Outbreak in China Coronavirus disease 19 infection The Chinese Centre for Disease Control and Prevention Phase Not Applicable Status not specified 0 44672 2020-04-09
Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment Coronavirus disease 19 infection, Scoliosis MAGEC Spine Rod alone, Titanium blood test alone Royal National Orthopaedic Hospital NHS Trust UK 2020-04-30 2021-03-31 NCT04337151, RNOH MAGEC Phase Not Applicable Recruiting 1 11 Months 100 Dr Harry Hothi, Harry Hothi, PhD 2020-04-16
SRA-COV: Renin Angiotesnin System - CoronaVirus Coronavirus disease 19 infection, Respiratory distress syndrome blood draw alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assistance Publique Hopitaux De Marseille France 2020-04-03 2020-07-31 2020-16, 2020-A00795-34, NCT04337008, SRA-COV Phase Not Applicable Recruiting 1 3 Months 50 Emilie Garrido-Pradalie, Francois Silhol, MD, François Silhol, MD 2020-04-10
Assessment of Distress in Crisis Situations During COVID-19 Coronavirus disease 19 infection, Post traumatic stress disorder Peritraumatic Distress Inventory alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Wefight France 2020-03-31 2020-05-31 NCT04337047, WEFIGHTDISTRESS20 Phase Not Applicable Recruiting 1 2 Months 2000 benjamin CHAIX 2020-04-16
CoV-Mortality: CoV-Mortality Coronavirus disease 19 infection National Institutes of Health Malaysia Malaysia 2020-04-15 2020-10-31 54609, CoV-Mortality, NMRR-20-691-54609 Phase Not Applicable Not yet recruiting 1 6 Months Dr. Woon Yuan Liang 2020-04-10
Effects of vitamin C supplementation on patients with COVID-19 Coronavirus disease 19 infection vitamin C alone Hospital Raja Permaisuri Bainun Malaysia 2020-04-14 2020-12-31 54478, IMVC 001, NMRR-20-684-54478 Phase Not Applicable Not yet recruiting 2 8 Months Dr Leong Chee Loon, Dr. G.R. Letchuman Ramanathan, Dr. Sharon Linus Lojikip, LIM XIN JIE 2020-04-10
COVID-19 ARDS Cyto-MSC Coronavirus disease 19 infection, Respiratory distress syndrome Cyto-MSC (umbilical cord derived mesenchymal stem cells) alone Cytopeutics Sdn Bhd Malaysia 2020-04-13 2020-05-31 54521, NMRR-20-672-54521, POD0039/CP/R Phase 1 Clinical Not yet recruiting 3 1 Month 5 Dr Chin Sze Piaw, Dr Toh See Guan, Mohd Shahrizal Bin Mohd Yusoff, Prof S FADILAH ABDUL WAHID 2020-04-10
A expanded access program of opaganib to treat patients with COVID-19 infection Coronavirus disease 19 infection opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV US Phase Not Applicable Planned 0 2020-04-08
A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection Coronavirus disease 19 infection hydroxychloroquine plus opaganib Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd Israel Phase Not Applicable Recruiting 1 2020-04-16
A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection with life-threatening clinical conditions Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia opaganib alone Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd Italy Phase Not Applicable Not yet recruiting 1 160 2020-04-14
Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine Coronavirus disease 19 infection social quarantine implementation alone Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Kultur University Istanbul University-Cerrahpasa Turkey 2020-04-12 2020-06-10 FADP-2, NCT04336787 Phase Not Applicable Not yet recruiting 1 1 Month 100 Ayse Zengin Alpozgen, assistant professor, Ayşe Zengin Alpözgen, Assistant Professor, Basak Polat, PhD Student, Başak Polat, PhD Student, Cicek Duman, PhD Student, Funda Akuzum, PhD Student, Funda Aküzüm, PhD Student, Gamze Ertürk Uzunoglu, PhD Student, Gamze Ertürk Uzunoğlu, PhD Student, Halenur Evrendilek, PhD Student, Tugce Tahmaz, PhD Student, Tuğçe Tahmaz, PhD Student, Çiçek Duman, PhD Student 2020-04-14
A phase II, single-arm, non-randomized study to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells in patients with high risk COVID-19 infection Coronavirus disease 19 infection autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hope Biosciences Inc Phase 2 Clinical Not yet recruiting 0 75 2020-04-16
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia mavrilimumab alone C-reactive protein inhibitor, Chemokine CC22 ligand inhibitor, GM-CSF receptor antagonist, Hemoglobin scavenger receptor antagonist, Metalloprotease-1 inhibitor, Metalloprotease-3 inhibitor, Small inducible cytokine A17 ligand inhibitor, VEGF gene inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Virginia Commonwealth University US 2020-04-30 2020-07-31 HM20019145, NCT04337216 Phase 2 Clinical Not yet recruiting 0 3 Months 10 Antonio Abbate, MD, PhD 2020-04-10
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia allogeneic human dental pulp stem cells (BSH BTC and Utooth BTC) alone, routine treatment alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Renmin Hospital of Wuhan University Beijing Scitop Bio-Tech Shareholding Co.Ltd, Utooth Biological Technology Co., Ltd. Hubei China 2020-04-06 2021-03-31 2020K-G005, HDPSC-COVID-2019-02-2020, NCT04336254 Phase 1/Phase 2 Clinical Recruiting 1 11 Months 20 Chenliang Zhou, PhD, Prof. Qingsong Ye, PhD,DDS, Qingsong Ye, PhD,DDS, Ye Qingsong 2020-04-09
Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course Coronavirus disease 19 infection HELIOS Kliniken GmbH Hygiene Helios Klinik Wuppertal, Klinikum Hildesheim GmbH Germany 2020-02-15 DRKS00021161, E-01-20200319 Phase Not Applicable Recruiting 1 1000 Julius Dengler, Michael Hauptmann 2020-04-10
An expanded access clinical study of autologous adipose-tissue derived mesenchymal stem cells (AdMSCs) multiple dose infusions for the treatment in patients with COVID-19 infection Coronavirus disease 19 infection autologous mesenchymal stem cell-derived exosomes (Alzheimers disease), Celltex Therapeutics alone Celltex Therapeutics Corp US Phase Not Applicable Planned 0 Dr. Derek W. Guillory 2020-04-08
COVID-ARA2: Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 Coronavirus disease 19 infection, Respiratory failure angiotensin II type 2 receptor agonists therapy alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Angers France 2020-04-03 2020-12-06 COVID-ARA2, COVID-ARA2, NCT04337190 Phase Not Applicable Recruiting 2 8 Months 100 Julien Demiselle, M.D., Julien Demiselle, MD, Pierre Asfar, MD, PhD 2020-04-13
CoCo Study: COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact Coronavirus disease 19 infection immunological analysis alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Hannover Medical School Deutsche Forschungsgemeinschaft (DFG), Deutsches Zentrum für Infektionsforschung, German Federal Ministry of Education and Research, Novartis Pharma GmbH Germany Germany 2020-04-05 8973_BO_K_2020, CoCo Study, DRKS00021152 Phase 1/Phase 2 Clinical Recruiting 1 1000 Georg Behrens 2020-04-15
Randomized, Comparison of Combination Azithromycin and Hydroxychloroquine versus Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 Coronavirus disease 19 infection, Viral pneumonia Plaquenil alone, Plaquenil plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rutgers University US 2020-04-01 2021-04-30 002011, NCT04336332, PRO2020000712 Phase 2 Clinical Recruiting 0 13 Months 160 Sabiha Hussain, MD, Shobha Swaminathan, MD, Steven K. Libutti, MD, FACS 2020-04-14
A clinical trial of IVIEW-1201 for the treatment or prevention of COVD-19 infection in the eye Coronavirus disease 19 infection povidone iodine (long acting/extended-release/gel, adenoviral conjunctivitis), IVIEW therapeutics alone iVIEW Therapeutics Inc China Phase Not Applicable Planned 1 2020-04-08
A pan-india non-interventional virtual registry evaluating the prophylactic efficacy of different regimens against SARS-CoV2 infection (COVID-2019) in asymptomatic health care workers Coronavirus disease 19 infection, SARS coronavirus infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Zifo RnD Solutions India 2020-04-17 CTRI/2020/04/024482 Phase Not Applicable Not yet recruiting 1 10000 Arvind Sri Krishna Mani, Viswanathan Niranjan 2020-04-10
Knowledge, attitude and fear of COVID-19 in Bangladesh Coronavirus disease 19 infection Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Centre for the Rehabilitation of the Paralysed Bangladesh 2020-04-09 CTRI/2020/04/024413 Phase Not Applicable Recruiting 1 1000 K M Amran Hossain, Md Zahid Hossain, Md. Shahoriar Ahmed, Professor Md Obaidul Haque 2020-04-10
ONCOVID: Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm Plaquenil plus azithromycin Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Institut Gustave Roussy France 2020-04-03 2022-04-30 2020-001250-21, 2020/3078, NCT04341207, ONCOVID Phase 2 Clinical Recruiting 2 24 Months 1000 Lisa DEROSA, MD, Stefan MICHIELS, MD 2020-04-13
CovidSurg-Cancer Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) The University of Birmingham Malaysia 2020-04-08 2021-03-31 NMRR-20-693-54498 Phase Not Applicable Not yet recruiting 1 11 Months 100 Andee Dzulkarnaen Zakaria 2020-04-13
Expanded-access study of GENOSYL DS for treating COVID-19 Infection Complicating Pulmonary Hypertension Coronavirus disease 19 infection, Pulmonary hypertension nitric oxide (GeNOsyl MV-2000, inhaled, ventilator platform), GeNO alone Vero Biotech 2020-03-31 Phase Not Applicable Recruiting 0 2020-04-09
EVALUATION: Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure Coronavirus disease 19 infection, Respiratory distress syndrome PiCCO-monitoring alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Ludwig-Maximilians University of Munich Technical University of Munich Germany 2020-03-11 2020-04-30 EVALUATION, ISRCTN10077335 Phase Not Applicable Recruiting 2 1 Month 25 Prof. Wolfgang Huber 2020-04-09
A phase II clinical study to assess VIR-7832 in the treatent of patients with SARS-CoV-2 infection Coronavirus disease 19 infection VIR-7832 alone Coronavirus spike glycoprotein inhibitor GlaxoSmithKline plc Vir Biotechnology Inc Phase 2 Clinical Planned 0 2020-04-08
A phase II clinical study to assess VIR-7831 in the treatent of patients with SARS-CoV-2 infection Coronavirus disease 19 infection VIR-7831 alone Coronavirus spike glycoprotein inhibitor GlaxoSmithKline plc Vir Biotechnology Inc Phase 2 Clinical Planned 0 2020-04-08
EasyCoV: Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2 Coronavirus disease 19 infection, SARS coronavirus infection sample collection alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) University Hospital, Montpellier Skillcell, Sys2Diag France 2020-04-07 2020-04-17 EasyCoV, NCT04337424, RECHMPL20_0170 Phase Not Applicable Not yet recruiting 1 180 REYNES Jacques, PU PH 2020-04-08
Imaging Findings In Covid-19 Coronavirus disease 19 infection Hospital Tawau Malaysia 2020-04-13 2020-04-30 NMRR-20-698-54570 Phase Not Applicable Not yet recruiting 1 70 Dr Mohana A/P Letchumanan 2020-04-08
Evaluation of Blood Results of Covid 19 Positive Pregnants Coronavirus disease 19 infection Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-03-21 2020-05-22 COVID19PREGNANCIES, NCT04337294 Phase Not Applicable No longer recruiting 1 2 Months 100 Pınar Yalcin bahat 2020-04-10
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 Coronavirus disease 19 infection, Viral pneumonia favipiravir alone, supportive care alone RNA polymerase inhibitor Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) ASST Fatebenefratelli Sacco Italy 2020-03-25 2020-07-31 HS216C17-PHASE III, NCT04336904 Phase 3 Clinical No longer recruiting 1 4 Months 100 Giuliano Rizzardini, Md 2020-04-09
REMOTE-COVID: Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus) Coronavirus disease 19 infection SensiumVitals wearable sensor alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Imperial College London UK 2020-04-01 2021-04-01 NCT04337489, REMOTE-COVID, REMOTE-COVID Phase Not Applicable Not yet recruiting 1 12 Months 200 Ara Darzi, Prof, Fahad M Iqbal, MBChB (hons), Sadia Khan, Dr 2020-04-08
Clinical and Radiomic Model of COVID-19 Coronavirus disease 19 infection Universiteit Maastricht Wuhan Central Hospital China 2019-12-23 2020-03-03 NCT04337502, UM_2020_GY_COVID-19 Phase Not Applicable Completed 1 2 Months 300 2020-04-10
UZH COVID-19 Cohort Study: Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center Coronavirus disease 19 infection Phone calls alone University of Zurich Switzerland 2020-03-20 2020-12-31 ISRCTN77353041, UZH COVID-19 Cohort Study Phase Not Applicable Recruiting 1 9 Months 200 Dr Dominik Menges, Prof Jan Fehr, Prof Milo A. Puhan 2020-04-09
Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns Coronavirus disease 19 infection Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-06-20 COVID19PREGNANCYNEWBORN, NCT04337320 Phase Not Applicable No longer recruiting 1 2 Months 70 Pınar Yalcin bahat 2020-04-08
Evaluation of the Effect of High-dose Vitamin C Use in Covid 19 Positive Pregnants Coronavirus disease 19 infection vitamin C alone Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-01 2020-05-30 HIGHDOSEVITCINCOVID19, NCT04337281 Phase Not Applicable No longer recruiting 1 1 Month 50 Pınar Yalcin bahat 2020-04-15
Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19) Coronavirus disease 19 infection, Viral pneumonia Xiaotan Sanjiefang granule alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) Beijing University of Chinese Medicine Chinese Ministry of Science and Technology China 2020-03-01 2020-12-31 ChiCTR2000031672, ChiMCTR2000003188 Phase 2 Clinical Not yet recruiting 1 10 Months 150 Yingshuai Li 2020-04-14
Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System Coronavirus disease 19 infection Surgical facial mask alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rigshospitalet, Denmark Denmark Technical University, HS Hvidovre Hospital, Nordsjaellands Hospital Denmark 2020-04-02 2020-07-01 2020-04-02, NCT04337541 Phase Not Applicable Recruiting 1 3 Months 6000 Christian Torp-Pedersen, Prof., DMSc, Henning Bundgaard, Prof., DMSc, Henrik Ullum, Prof., DMSc, Kasper Karmark Iversen, Prof., DMSc, Thomas Benfield, Prof., DMSc 2020-04-15
Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients Coronavirus disease 19 infection, Viral pneumonia interferon treatment alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Wenzhou Central Hospital China 2020-02-01 2021-01-31 ChiCTR2000031699 Phase 1 Clinical No longer recruiting 1 12 Months 33 Tangshaohua 2020-04-09
Evaluation of Covid 19 Anxiety in Endometriosis Patients Coronavirus disease 19 infection, Endometriosis, Generalized anxiety disorder Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Istanbul Bakirkoy Maternity and Children Diseases Hospital Turkey 2020-04-05 2020-04-25 ENDOCOVID19, NCT04337346 Phase Not Applicable No longer recruiting 1 80 Pınar Yalcin bahat 2020-04-09
COVID-CHD: Impact of Covid-19 in Congenital Heart Disease Congenital heart defect, Coronavirus disease 19 infection University Hospital, Montpellier France 2020-03-01 2020-12-30 COVID-CHD, NCT04336384, RECHMPL20_0155 Phase Not Applicable Recruiting 1 9 Months 5000 Adeline BASQUIN, MD, Alexis BLANC, MD, BERTRAND LEOBON, MD, Caroline OVAERT, MD, Céline GRUNENWALD GRONIER, MD, Daniela LAUX, MD, Hamouda ABASSI, MD, Jean-Benoît THAMBO, MD, PhD, Karine WARIN-FRESSE, MD, Magalie LADOUCEUR, MD, Nicolas COMBES, MD, Pascal AMEDRO, MD-PHD, Pascal AMEDRO, MD-PhD, Roland HENAINE, PU PH, Sébastien HASCOET, MD, Xavier IRIART, MD 2020-04-15
Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease Coronavirus disease 19 infection Ig G test alone, Questionnaire alone Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Assiut University Egypt 2020-04-30 2020-05-31 ASSIUTU11, NCT04336657 Phase Not Applicable Recruiting 1 1 Month 100 Aliae AR Mohamed-Hussein, Aliae Mohamed-Hussein 2020-04-09
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Coronavirus disease 19 infection, SARS coronavirus infection hydroxychloroquine alone Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Medical University of Vienna 2020-04-30 2020-08-31 HCQ PROPHYLAXIS FOR COVID19, NCT04336748 Phase 3 Clinical Not yet recruiting 0 4 Months 440 Matthias Vossen 2020-04-09
CAPTION AI to Minimize Risk of COVID Exposure Coronavirus disease 19 infection, Viral pneumonia Caption AI alone Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Duke University Caption Health Inc US 2020-04-30 2020-11-09 NCT04336774, PRO00105212 Phase Not Applicable Not yet recruiting 0 6 Months 500 Kristine Arges, BSN, Sreekanth Vemulapallli, MD 2020-04-09
INCOVPED: Prevalence of Covid-19 in Children Admitted to Pediatric Emergency Departments During the Pandemic Period in France Coronavirus disease 19 infection nasopharyngeal swab alone Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) Centre Hospitalier Regional Universitaire de Lille France 2020-04-30 2020-12-31 2020-A00811-38, 2020_21, INCOVPED, NCT04336761 Phase Not Applicable Not yet recruiting 5 8 Months 914 Camille BREHIN, MD, Christèle LE GUEN, MD,PhD, Flora JOANNES, MD, François DUBOS, MD,PhD, François Dubos, MD,PhD, Hervé HAAS, MD, Marie Chinazzo-Vigouroux, MD 2020-04-09
A trial to assess brilacidin in the potential treatment of novel coronavirus COVID-19 treatment Coronavirus disease 19 infection brilacidin alone PDE 3 inhibitor, PDE 4 inhibitor Innovation Pharmaceuticals Inc Europe Phase Not Applicable Planned 0 2020-04-08
Rutgers COVID-19 Cohort Study Coronavirus disease 19 infection Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Rutgers University US 2020-04-07 2021-10-21 2020000679, NCT04336215 Phase Not Applicable Recruiting 0 18 Months 750 Jeffrey L Carson, MD, Reynold A Panettieri, MD 2020-04-16
MexCOVID-19: Outcomes of Patients With COVID-19 in the Intensive Care Unit Coronavirus disease 19 infection Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) Instituto Nacional de Ciencias Medicas y Nutricion Mexico 2020-04-01 2020-05-30 MexCOVID-19, NCT04336345, TEI-3336-20-20-1 Phase Not Applicable Not yet recruiting 2 1 Month 150 Eduardo Rivero-Sigarroa, MD, Guillermo Dominguez-Cherit, MD, Silvio A. Ñamendys-Silva, MD, MSc 2020-04-09
Viral Infection and Respiratory illness Universal Study Coronavirus disease 19 infection, Viral pneumonia Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) Society of Critical Care Medicine US, India, Italy, UK 2020-04-01 CTRI/2020/04/024473 Phase Not Applicable Recruiting 3 50000 Dr Mradul Kumar Daga, Dr Naresh Kumar 2020-04-09
A multicenter, phase 2/3, randomized, placebo-controlled study to assess the effect of remestemcel-L in the treatment of COVID-19 patients with acute respiratory distress syndrome Coronavirus disease 19 infection, Respiratory distress syndrome remestemcel-L alone Mesoblast Ltd, National Heart Lung and Blood Institute US Phase 2/Phase 3 Clinical Not yet recruiting 0 2020-04-13